Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus – International Task Force

Sanjay Kalra, Silver Bahendeka, Rakesh Sahay, Sujoy Ghosh, Fariduddin Md, Abbas Orabi, Kaushik Ramaiya, Sameer Al Shammar, Dina Shrestha, Khalid Shaikh, Sachitha Abhayaratna, Pradeep K. Shrestha, Aravindan Mahalingam, Mazen Askhet, Aly Ahmed R. Rahim, Fatimah Eliana, Hari K. Shrestha, Sandeep Chaudhary, Nancy Ngugi, Jean Claude Mbanda, Than Tha Aye, Tint Swe Latt, Zhanay A. Akanov, Abbas RazaSyed, Nikhil Tandon, A. G. Unnikrishnan, S. V. Madhu, Ali Javaid, Subhankar Chowdhury, Sarita Bajaj, Ashok Kumar Das

Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India, Department of Internal Medicine, Diabetes & Endocrinology, St. Francis Hospital, Nsamba, Kampala, Uganda, Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, Department of Endocrinology, IPGMER and SSKM Hospital, Kolkata, West Bengal, India, Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt, Department of Internal Medicine, Hindu Mandal Hospital, Dar es Salaam, Tanzania, Department of Endocrinology, Al Jahra Hospital, Al Jahra, Kuwait, Department of Endocrinology, Norvic International Hospital and Medical College, and Hospital for Advanced Medicine and Surgery, Maharajganj, Kathmandu, Nepal, Department of Diabetes, Faculty of Internal Medicine, Royal Oman Police Hospital, Muscat, Oman, Department of Pharmacology, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka, Department of Medicine, Tribhuvan University Teaching Hospital, Maharajganj, Kathmandu, Nepal, Department of Medicine, Teaching Hospital, Jaffna, Sri Lanka, Department of Medicine, Tawam Hospital, Al Ain, UAE, Department of Internal Medicine, Diabetes & Metabolism Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt, Department of Internal Medicine, Faculty of Medicine, YARSI University, Jakarta, Indonesia, Department of Internal Medicine, Kathmandu University Hospital, Dhulikhel, Nepal, Department of Endocrinology, ADK Hospitals, Male, Maldives, Department of Endocrinology, Kenyatta National Hospital, Nairobi, Kenya, Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé, Yaoundé, Cameroon, Department of Endocrinology, University of Medicine 2, Yangon, Department of Medicine, University of Medicine 2, Yangon, Myanmar, Center of Diabetes, Clinic of Internal Diseases, Astendiyarov Kazakh National Medical University, Almaty, Republic of Kazakhstan, Department of Endocrinology, Shaukat Khanum Hospital and Research Center, Lahore, Pakistan, Department of Endocrinology, Metabolism and Diabetes, All India Institute of Medical Sciences, Department of Endocrinology and Diabetes, Chellaram Diabetes Institute, Pune, Maharashtra, Department of Medicine, University of Delhi, New Delhi, India, Department of Endocrinology, Diabetes and Metabolism, Wilshire Cardiovascular and Endocrine Center of Excellence, Lahore, Pakistan, Department of Medicine, MLN Medical College, Allahabad, Uttar Pradesh, Department of General Medicine, Pondicherry Institute of Medical Sciences, Puducherry, India

Abstract

For decades, sulfonylureas (SUs) have been important drugs in the antidiabetic therapeutic armamentarium. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. It has to be borne in mind that the adverse events associated with SUs should not be ascribed to the whole class, as many modern SUs, such as glimepiride and gliclazide modified release, are associated with better safety profiles. Furthermore, individualization of treatment, using SUs in combination with other drugs, backed with careful monitoring and patient education, ensures maximum benefits with minimal side effects. The current guidelines, developed by experts from Africa, Asia, and the Middle East, promote the safe and smart use of SUs in combination with other glucose-lowering drugs.

Keywords: Gliclazide, glimepiride, sulfonylurea, type 2 diabetes

Executive Summary

Sulfonylures (SUs) in oral combination therapy:
• A1. Modern SUs (glimepiride and gliclazide modified release [MR]) are effective and safe second-line agents in patients who have not achieved predecided glycemic targets with metformin monotherapy (Grade A; evidence level [EL] 1)

Address for correspondence: Dr. Sanjay Kalra, Department of Endocrinology, Bharti Hospital, Karnal, Haryana, India.
E-mail: brideknl@gmail.com

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Kalra S, Bahendeka S, Sahay R, Ghosh S, Md F, Orabi A, et al. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International task force. Indian J Endocr Metab 2018;22:132-57.
• A2. Modern SUs are effective and safe as initial therapy if used in combination with lifestyle modification and metformin, in patients with a baseline glycated hemoglobin ≥7.5% (Grade A; EL 1)

• A3. SUs may be considered for use in combination with all classes of oral antidiabetic drugs except glinides (Grade A, EL1)

• A4. If not used earlier, modern SUs may be preferred as third-line agents for the management of uncontrolled diabetes with dual combination therapy, owing to better safety profile than older SUs (Grade A, EL 1)

• A5. Fixed-dose combinations (FDCs) containing SUs reduce cost, offer convenience, and improve patient adherence (Grade B; EL 1); hence, FDCs with varying strengths of SU + metformin should be made available, while SU + other drugs may be considered (Grade A; EL 4).

Comparative assessment as dual therapy with metformin:

• B1. Compared to metformin up titration beyond half-maximal dose, the addition of SU to metformin demonstrates better glucose-lowering efficacy, safety, and tolerability (Grade A, EL 1)

• B2. Compared to pioglitazone, SUs demonstrate good glucose-lowering efficacy with significantly lower risk of weight gain (Grade A, EL 1)

• B3. Compared to dipeptidyl peptidase 4 inhibitors, SUs demonstrate better and more durable glucose-lowering efficacy; however, the likelihood of increase in body weight and risk of hypoglycemia should be taken into consideration (Grade A, EL 1)

• B4. Compared to sodium glucose co-transporter 2 inhibitors, SUs show noninferior glycemic control; however, safety criteria need to be considered while preferring either class (Grade A, EL 1)

• B5. Compared to glucagon-like peptide 1 receptor agonists, SUs show similar glycemic efficacy, with acceptable safety at lower cost (Grade A, EL 1).

SU and insulin combination:

• C1. Modern SUs may be continued, with appropriate precaution, when basal insulin is initiated (Grade A; EL 1)

• C2. Modern SUs may be continued, in the antipodal meal, if premixed insulin is initiated once daily (Grade A; EL 1)

• C3. Short-acting SUs, or glinides, may be continued or added to the third meal, with appropriate glucose monitoring if premixed insulin is initiated twice daily (Grade B; EL 1).

Use in special populations:

• D1. Combinations containing modern SUs can be used in elderly patients as they are associated with low risk of hypoglycemia (Grade A; EL 1)

• D2. SUs (glibenclamide) may be used in the glycemic control of neonatal diabetes (KCNJ11, ABCC8 gene mutations) and Maturity-Onset Diabetes of the Young 3 (MODY 3) (Grade A; EL 3)

• D3. The evidence base for the use of SUs in adolescents with type 2 diabetes is limited (Grade A; EL 4)

• D4. There is insufficient evidence to recommend the use of SUs, as monotherapy or in combination, to be used during pregnancy and lactation (Grade A; EL 2).

Use in comorbid conditions:

• E1. There is insufficient evidence to suggest that modern SUs increase cardiovascular (CV) risk. Modern SUs are preferred over conventional SUs in patients with diabetes and cardiovascular disease (CVD) (Grade A; EL 1)

• E2. Among SUs, short-acting drugs, especially those metabolized in the liver (glipizide), should be preferred in patients with moderate/severe renal impairment. In mild/moderate renal impairment, modern SUs may also be used, preferably at lower doses (Grade A; EL 3)

• E3. Reductions of SU dose and/or longer intervals between

---

Table 1: Classification of sulfonylureas

| Classification based on hierarchy of development | Conventional | Modern |
|-----------------------------------------------|--------------|--------|
| Short acting                                  | TOLB         | GLIM, GLIC, GLIC MR, GLIP MR/XL |
| Intermediate acting                           | GLIB, GLIC, glipidone |
| Long acting                                   | CHOL, GLIB, GLIM, GLIC MR, GLIP MR |

Table 2: Sulfonylureas listed in the National List of Essential Medicines of different countries in Africa, Middle East and North Africa, and South East Asian region

| Countries/drugs | GLIB | GLIC | GLIP | GLIM |
|-----------------|------|------|------|------|
| Bahrain         | Yes  | Yes  | Yes  | Yes  |
| Bangladesh      | Yes  | Yes  | No   | No   |
| Egypt           | Yes  | No   | No   | No   |
| India           | No   | No   | No   | Yes  |
| Indonesia       | Yes  | No   | Yes  | No   |
| Kenya           | Yes  | Yes  | No   | No   |
| Kuwait          | Yes  | Yes  | No   | No   |
| Maldives        | Yes  | Yes  | Yes  | Yes  |
| Myanmar         | Yes  | Yes  | Yes  | Yes  |
| Nepal           | Yes  | No   | No   | No   |
| Nigeria         | Yes  | Yes  | No   | No   |
| Oman            | Yes  | Yes  | Yes  | Yes  |
| Pakistan        | Yes  | No   | No   | No   |
| Qatar           | Yes  | Yes  | Yes  | Yes  |
| Saudi Arabia    | Yes  | Yes  | Yes  | Yes  |
| South Africa    | Yes  | No   | No   | Yes  |
| Sri Lanka       | Yes  | No   | No   | No   |
| Tanzania        | Yes  | Yes  | Yes  | No   |
| The UAE         | Yes  | Yes  | Yes  | Yes  |
| Uganda          | Yes  | No   | No   | Yes  |

UAE: United Arab Emirates, GLIB: Glibenclamide, GLIP: Glipizide, GLIM: Glimepiride, GLIC: Gliclazide

---

Kalra, et al.: Sulfonylurea and combinations: International Task Force
Sulfonylurea and combinations: International Task Force

**Table 3: A complete list of situational analysis of sulfonylureas and sulfonylurea combinations in participating countries**

| Countries    | Prevalence (%) | Monotherapy available                                                                 | FDCs (OADs) available |
|--------------|----------------|----------------------------------------------------------------------------------------|-----------------------|
| Bangladesh   | 7.1 million    | GLIM, GLIC MR, GLIP, and GLIB                                                         | GLIM/MET             |
| Egypt        | 8.3            | GLIM, GLIC MR, GLIP, and GLIB                                                         | GLIM/MET             |
| India        | 10-14          | GLIM replaced GLIM in NELM 2015                                                        | GLIM/MET             |
|              |                | GLIM, GLIC, GLIC MR, GLIP, and GLIB                                                   | GLIC MR/MET          |
|              |                | GLIM, GLIC, GLIC MR, and GLIB                                                         | GLIC/MET             |
|              |                | GLIM, GLIC, GLIC MR, GLIP, and GLIB                                                   | GLIC/MET             |
| Indonesia    | 9.1            | SU are the first priority among other OADs                                             | GLIM/MET             |
|              |                | GLIM, GLIC, GLIC MR, GLIP, gliclizide, and GLIB                                       | GLIC/MET             |
| Kuwait       | 21             | GLIM, GLIC, MR, and GLIB                                                              | GLIM/MET             |
| Maldives     | 8              | GLIM, GLIC, GLIP, and GLIB                                                            | GLIM/MET             |
| Myanmar      | 10.5           | GLIM, GLIC, GLIP, and GLIB                                                            | GLIM/MET             |
| Nepal        | 5.6            | GLIM, GLIC, GLIC MR, GLIP, and GLIB                                                   | GLIM/MET             |
| Oman         | 13-14          | All SUs except first-generation SUs                                                   | No SU FDC            |
| Pakistan     | 6.9            | GLIM, GLIC MR, GLIP, and GLIB                                                         | GLIM/MET             |
| Sri Lanka    | 10-12          | GLIM, GLIC, GLIC MR, GLIP, TOLB, and GLIB                                             | No FDCs for diabetes |
| Tanzania     | 9.8            | GLIM, GLIC MR, CHOL, and GLIB                                                         | GLIM/MET             |
| The UAE      | 20             | GLIM, GLIC, GLIC MR, and GLIB                                                         | GLIM/MET             |
| Uganda       | 1.4            | GLIM and GLIB                                                                         | GLIM/MET             |

**Note:**
- CHOL: Chlorpropamide, DPP-4I: Dipeptidyl peptidase 4 inhibitor, FDC: Fixed-dose combinations, GDM: Gestational diabetes mellitus, GLIB: Glibenclamide, GLIC: Gliclazide, GLIP: Glipizide, GLIM: Glimepiride, MENA: Middle East and North Africa, MET: Metformin, MR: Modified release, NELM: National Essential List of Medicines, OADs: Oral antidiabetic agents, PIO: Pioglitazone, SEA: South East Asia, SGLT-2I: Sodium glucose cotransporter-2 inhibitor, SITA: Sitagliptin, SUs: Sulfonylureas, TOLB: Tolbutamide, VOGL: Voglibose, UAE: United Arab Emirates

SUs in combination and Ramadan:
- **F1.** Modern SUs may be used in combination with other drugs during Ramadan, with appropriate counseling and dose modification (Grade A; EL 3)
- **F2.** Individuals on once-daily SU should take their medication at Iftar (evening meal) (Grade A; EL 3)
- **F3.** Individuals on twice-daily SU may shift the morning dose to Iftar and half of the evening dose to Suhur (morning meal) (Grade A; EL 4)
- **F4.** Patients on SU and premixed insulin should consider reducing the dose of either drug or shifting from premix to low-peak basal insulin during Ramadan (Grade A; EL 4)
- **F5.** Dose titration during Ramadan should be based on twice-weekly or weekly glucose monitoring (Grade A; EL 3).

**INTRODUCTION**

**Epidemiology and burden of diabetes**

Type 2 diabetes mellitus (T2DM), a progressive metabolic disorder, is continuously gaining the status of a potential epidemic in the world. According to the 2015 global estimates of International Diabetes Federation (IDF), about 415 million people (1 in 11 adults) have been shown to present with diabetes and is expected to reach 642 million (1 in 10 adults) by 2040. Moreover, around 318 million adults are associated with impaired glucose tolerance, who...
are at a high risk of developing diabetes in the future. The 2015 regional fact sheet of IDF estimates the prevalence to be 10.7%, 8.5%, and 3.2% in the Middle East and North Africa (MENA), South East Asia (SEA), and African regions, respectively.\(^1\) This increasing burden of the disease may contribute to increased rate of complications, reduction of quality of life, and premature mortality. As per the 2016 World Health Organization (WHO) global report on diabetes, the high blood glucose age-standardized mortality rates are 139.6, 115.3, and 111.3/100,000 in WHO Eastern Mediterranean, South-East Asia, and African regions, respectively.\(^1\)

**Prescription pattern of oral antidiabetic drugs**

Tight glycemic control reduces the associated complications and improves the quality of life in patients with T2DM. The United Kingdom Prospective Diabetes Study trial reported that each 1% reduction of glycated hemoglobin (A1C) decreases approximately 12%–43% risk of diabetes-related mortality and morbidity.\(^2\) Numerous antidiabetic agents are currently available as monotherapy or in combination therapy for the treatment of T2DM. However, oral antidiabetic drugs (OADs) still dominate the prescribing pattern (56.4%) followed by insulin alone (43.6%).\(^3,4\) Furthermore, sulfonylureas (SUs) alone or in combination with metformin have been the most commonly prescribed OADs in some Afro-Asian countries.\(^6,9\)

SUs can be classified either according to their hierarchy of development (conventional and modern SUs) or based on the duration of action (short-, intermediate-, and long-acting). The classification has been described in Table 1. This helps to avoid confusion during their use and can be effectively utilized in patients with variable clinical scenario.

**Situational analysis of sulfonylureas**

The conventional or modern SUs are widely used as second-line agents in the management of T2DM in most countries of Africa, MENA, and SEA region due to low cost and high efficacy. Among all, the combination of glimepiride (GLIM) and metformin is available in most of these countries. The National List of Essential Medicines (NLEM) in different countries containing SUs along with metformin is shown in Table 2. In 2015, the Indian NLEM was updated to align with the current treatment guidelines. Where more drugs were available within a therapeutic class, the core committee considered the best-suited one after due deliberation and careful evaluation of their relative safety, efficacy, and cost. Accordingly, glibenclamide (GLIB) has been replaced with GLIM in the diabetes section.\(^10\) Tolbutamide (TOLB) and chlorpropamide (CHOL) are still used in Sri Lanka and Tanzania, respectively; gliquidone is available in Indonesia and Egypt. Fixed-dose combinations (FDCs) containing either conventional or modern SUs are available in most of the countries in Africa, MENA, and SEA regions except Oman and Sri Lanka. Furthermore, basal or premix insulin in combination with SUs is also prescribed for the management of T2DM in different parts of the world. A complete list of situational analysis of SUs in participating countries is summarized in Table 3.

**Rationale and Methodology**

**Pathophysiological basis**

During the course of treatment, progressive nature of T2DM with a gradual decline in the functional β-cells leads to continuing the decrease in the glucose-lowering efficacy of OADs over time.\(^11\) Evidence suggests that early combination therapy with intensive glycemic control can be an effective approach for better preservation of β-cell function, which may quickly attain the target glycemic level and reduce diabetic-related complications.\(^12-17\) Early introduction of combination therapy also reduces complications associated with up titration of monotherapies. The delay in stepping up from monotherapy to combination therapy in the step-wise approach contributes to long periods of hyperglycemia and an increased risk of macro- and microvascular complications.\(^18\)

**Pharmaceutical advances**

Metformin produces its antihyperglycemic action without affecting the insulin secretion; hence, it is beneficial in combining metformin with insulin secretagog, like an SU. Among OADs available as add-on therapies to metformin, modern SUs can be considered as an ideal option owing to their high efficacy, relative cardiovascular (CV) safety, and low cost. The risk of hypoglycemia and weight gain can be minimized using modern SUs such as GLIM and gliclazide (GLIC) modified release (MR) with fewer side effects and better efficacy, which also has contributed to their wider use. Furthermore, combination therapies show a greater blood glucose-lowering effect than that of a single agent, which has been demonstrated in a number of studies and has resulted in the marketing of FDC preparations.\(^11,19\)

| Table 4: Evidence and recommendation grading according to the American Association of Clinical Endocrinologists guideline |
|---------------------------------------------------------------|
| **Evidence level** | **Semantic descriptor (reference methodology)** | **Grades** | **Recommendation** |
|-------------------|-------------------------------------------------|------------|-------------------|
| 1                 | Meta-analysis of RCTs, RCTs                      | A          | Strong            |
| 2                 | Meta-analysis of nonrandomized prospective or case-controlled trials, non-RCT, prospective cohort study, retrospective case-control study | B          | Intermediate      |
| 3                 | Cross-sectional study, surveillance study (registries, surveys, epidemiologic study, retrospective chart review, mathematical modeling of database), consecutive case series, single case reports | C          | Weak              |
| 4                 | No evidence (theory, opinion, consensus, review, or preclinical study) | D          | No evidence       |

AACE: American Association of Clinical Endocrinologists, RCTs: Randomized controlled trials
Table 5: Sulfonylureas with respect to their generation, history of development, duration of action, and other pharmacokinetic/pharmacodynamic profile (adapted from)

| PK/PD properties | GLIB | GLIC | GLIP | GLIM | GLIP XL | GLIC MR |
|------------------|------|------|------|------|---------|---------|
| Generation       | Second | Second | Second | Third | Third | Third |
| History of development | 1984 | 1984 | 1984 | 1995 | 1995 | 1995 |
| Duration of action (h) | 16-24 | 10-24 | 12-24 | 24 | >24 | >24 |
| V_d (L) | 9-10 | 13-24 | 10-11 | 19.8-37.1 | 10 | 19 |
| Protein binding (%) | 99 | 85-99 | 98-99 | 99 | 98-99 | >90 |
| Metabolism | Hepatic (no active metabolites) | Hepatic | | | | |
| Bioavailability (%) | 99 | 80 | 100 | 100 | 100 | 97 |
| Half-life (h) | 10 | 8-12 | 2-5 | 5 | 2-5 | 16 |
| Time to peak (h) | 2-4 | 2-4 | 1-3 | 2-3 | 6-12 | 6-7 |
| Excretion | 50% renal | 80% renal | 80% renal | 60% renal | 80% renal, 10% feces | <60%-70% renal, 10%-20% feces |

Drug-drug interaction: May interact with CYP2C9 inducers or inhibitors
PK changes in the elderly: Slow elimination; the high volume of distribution likely increase and slower elimination
PK changes in renal and hepatic impairment: May be altered; risk of toxic reactions to the drug increases May affect the distribution; reduce the capacity for metabolism and excretion may be slowed No significant differences in PK properties May affect the disposition of drug; diminish gluconeogenic capacity May affect the distribution; reduce the capacity for neoglucogenesis; the risk of hypoglycemia increases

V_d: Volume of distribution, MR: Modified release, XL: Extended release, PK/PD: Pharmacokinetics/pharmacodynamics, GLIB: Glibenclamide, GLIC: Gliclazide, GLIP: Glipizide, GLIM: Glimepiride

Methodology
The current consensus reviews the recent evidence on SUs and presents evidence-based recommendations on the use of SUs and their combination for the management of T2DM. In order to impart the highest possible evidence base for the use of SUs in combination in the management of T2DM, a systematic review of the literature was initiated. Existing guidelines, meta-analyses, systematic reviews, randomized controlled trials (RCTs), non-RCTs, and key cited articles relating to T2DM management were reviewed and recommendations were framed. Recommendations for each section of the consensus statement were discussed by the expert panels and where there was a little or no evidence, the panel relied on logical empiricism and consensus to make their recommendations. The current consensus is developed in accordance with the American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines. Recommendations are based on clinical importance (graded as A: strong, B: intermediate, C: weak, and D: no evidence based), which were coupled with four intuitive levels of evidence (1 = “at least one RCT or meta-analysis of RCTs,” 2 = “at least one nonrandomized or noncontrolled, prospective epidemiological study,” 3 = “cross-sectional or observational or surveillance or pilot study,” and 4 = “existing guideline or consensus expert opinion on extensive patient experience or review”) [Table 4].

Sulfonylureas and Type 2 Diabetes Mellitus
SUs have been a cornerstone in the T2DM management for the past 60 years. TOLB was the first SU marketed in the 1950s. This was followed by the introduction of the other first-generation agents such as CHOL, acetohexamide, and tolazamide. The next advancement in SU therapy was the development of potent second-generation agents such as GLIB and glipizide (GLIP) in the year 1984 in the United States. Furthermore, GLIM, a third-generation agent with eminent characteristics, was released into the market in the year 1995. SUs with respect to their generation, history of development, duration of action, and other pharmacokinetic/pharmacodynamics profiles are described in Table 5. SUs have been categorized as insulin secretagogues. They act by stimulating the pancreatic β-cells to secrete insulin. SUs mainly bind to the SU receptors (SURs), a subunit of potassium ATP-dependent (K_ATP) channels located in the β-cell membrane, which eventually blocks the potassium channels and facilitates the influx Ca^{2+} into the cell. This leads to cell depolarization and subsequently accelerates insulin exocytosis [Figure 1a]. Furthermore, owing to their cell-mediated and nonglucose-mediated action, all SUs are more effective in the early stages of T2DM when the β-cell function is to its greatest ability. All the SUs are eliminated by liver and kidney and well tolerated by adult patients; however, hypoglycemia and weight gain are the concerns with conventional SUs.

The affinity of SUs varies with different SUR subunits present in K_ATP channels. It is reported that GLIB blocks both...
SUR \(_1\) (pancreatic \(\beta\)-cells) and SUR \(_2\) (cardiac and skeletal muscles) subunits with similar affinity. The modern SU, GLIM, blocks SUR \(_1\) and preferentially the sarcolemmal SUR \(_2\) while sparing the mitochondrial SUR. A number of studies, however, have demonstrated that GLIM does not have a negative impact on cardiac function and has less effect on the electrical properties of the heart.\(^{[27,28]}\) GLIC and TOLB selectively block only SUR \(_1\) compared to SUR \(_2\).\(^{[29,30]}\) The affinity of SUR \(_1\) protein toward sulfonyl moiety is 100–1000 folds more compared to SUR \(_2\) protein.\(^{[31]}\) Furthermore, GLIC is the only SU which does not bind to the Epac2 receptor [Figure 1b]\(^{[31]}\), a stimulating factor for insulin exocytosis, which may confer a lower risk of hypoglycemia.\(^{[5,32]}\) Similarly, GLIM also confers a low rate of hypoglycemia and weight gain than conventional SUs due to its lower binding affinity (2–3 folds) and quick association and dissociation with SUR proteins.\(^{[33-35]}\) Furthermore, SUs inhibit the mitochondrial K\(_{ATP}\) channels in cardiac myocytes, which contributes to impairment of ischemic preconditioning; however, GLIM does not exert this effect and preserves myocardial ischemic preconditioning.\(^{[5]}\) Moreover, a lesser pancreatic overstimulation and resultant low hypoglycemia by GLIC could be due to the restoration of the early insulin peak in response to glucose stimulation and higher reversibility of binding of GLIC to the SUR1 of \(\beta\)-cell.\(^{[36]}\) In addition, modern SUs also exhibit certain pleiotropic effects such as insulin clearance, glucagon secretion, insulin sensitization, anti-oxidative effect, angiogenesis, vascular health, and ischemic preconditioning.\(^{[5]}\)

**Summary of guidelines recommending SUs and combinations for the management of type 2 diabetes mellitus**

The addition of SUs has been the gold standard combination therapy for decades in patients who fail to achieve target glycemic control with metformin monotherapy.\(^{[37]}\) In addition, pertaining to their low cost and high efficacy, SUs are widely used as a second-line agent in different regions of the world for the management of diabetes. Moreover, modern SUs such as GLIM and GLIC MR are preferred over other SUs in diabetic patients due to low risk of hypoglycemia and CV neutrality.\(^{[36,38-40]}\) A summary of guidelines recommending SUs in combination therapy for the management of T2DM in various countries is depicted in Table 6.

**Sulfonureas and Combinations in the Management of Type 2 Diabetes Mellitus**

**Sulfonurea + metformin**

**Mechanism**

A combination of two drugs with the complementary mechanism of action may help in addressing multiple etiologies of hyperglycemia in patients with T2DM.\(^{[5]}\) Metformin has insulin-sensitizing properties. It facilitates insulin uptake by the peripheral tissues and enhances the glucose utilization in adipose and intestinal tissues. SUs increase the sensitivity of \(\beta\)-cells to glucose and facilitate endogenous secretion of insulin. Furthermore, both metformin and SUs may reduce hepatic glucose
overproduction by decreasing hepatic gluconeogenesis and glycogenolysis; however, the relative contribution of gluconeogenesis and glycogenolysis by metformin remains controversial.\textsuperscript{[56,57]} Moreover, SUs may inhibit secretion of glucagon from islet cells\textsuperscript{[58]} and also stimulate glycogen synthesis in the liver.\textsuperscript{[57]} Diagrammatic representation of the complementary mechanism is shown in Figure 2.

\textbf{Glycemic efficacy}

The addition of SUs to ongoing metformin monotherapy has shown good glycemic control with acceptable safety and tolerability in numerous meta-analyses and RCTs.

\textbf{Sulfonylureas add-on to metformin versus metformin monotherapy}

A meta-analysis of 15 RCTs each lasting <1 year compared metformin monotherapy with the combination of metformin and SUs. All included studies favored the combination arm over monotherapy for glycemic efficacy with a pooled between-group difference of 0.9% (95% confidence interval [CI]: 0.7%–1.2%).\textsuperscript{[59]} In another meta-analysis, when SU was added to oral medication, A1C was reduced by 1.62% (95% CI: 1.00, 2.24; $I^2 = 94.1\%$) in the SU group than in the comparator group.\textsuperscript{[60]} A placebo-controlled study by Ahren \textit{et al.} with a duration lasting up to 104 weeks compared metformin (>1500 mg daily) with the combination of metformin (≥1500 mg daily) plus GLIM (up to 4 mg daily). The study showed a between-group difference in A1C of 0.63% at the end, favoring the combination arm.\textsuperscript{[61]} In a randomized, open-label, parallel group, multicenter trial, GLIM/metformin FDC therapy provided significantly greater adjusted mean decreases in A1C (−1.2 vs. −0.8%, $P < 0.0001$) and fasting plasma glucose (FPG) (−35.7 vs. −18.6 mg/dL, $P < 0.0001$) compared
Table 7: Summary of randomized controlled trials evaluating different sulfonylureas in combination with metformin compared to metformin monotherapy

| Author                         | Intervention                                                                 | Glycemic efficacy                                                                 | Adverse events                                                                 | Weight gain | Conclusion                                                                 |
|-------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------|---------------------------------------------------------------------------|
| Charpentier et al., 2001[64]  | GLIM + metformin (A) versus metformin (B) with monotherapy failure          | ↓ A1C (A vs. B): −0.74±0.96 versus+0.07±1.20%; P<0.001                           | The incidence of symptomatic hypoglycemia was higher with A than B (P=0.039)    | -           | Addition of GLIM in T2DM patients uncontrolled by metformin alone resulted in superior glycemic control than metformin monotherapy |
| González-Ortiz et al., 2004[65]| GLIM + metformin (A) versus metformin (B)                                    | ↓ A1C (A vs. B): −1.3±1.8 versus −0.7%±2.1% Percentage of patients showed ↓ A1C (≥1%) (A vs. B): 47.0% versus 21.2%; P<0.001 | The frequency of adverse events was similar for both the groups                | -           | The combined use of GLIM-metformin in a single presentation was efficacious and safe in patients with T2DM                     |
| Kim et al., 2014[62]          | GLIM-metformin FDC (A) versus metformin up titration (B)                      | ↓ A1C (A vs. B): −1.2% versus −0.8%, P<0.0001                                   | Hypoglycemia (A vs. B): 41% versus 5.6%, P<0.0001                              | -           | FDC was more effective than metformin up titration                          |
| Ristic et al., 2007[60]       | GLIC + metformin versus nateglinide + metformin                              | Change from baseline to 52 weeks for GLIC combination: A1C, −0.27% (P=0.396); FPG, −0.7 mmol/l (P=0.096) | Metformin-GLIC combination is effective in uncontrolled T2DM patients           | -           |                                                                            |
| Goldstein et al., 2003[67]    | GLIP/metformin combination (A) versus metformin or GLIP monotherapy (B)      | ↓ A1C (A vs. B): −1.06% versus −0.98%, P<0.001                                  | Both treatments were well tolerated, with a low incidence of symptoms of hypoglycemia | -           | Combination was more effective in controlling A1C and FPG in uncontrolled T2DM patients with monotherapies                    |
| Feinglos et al., 2005[68]     | GLIP GITS (A) versus placebo (B), both added to metformin ≥1000 mg/day for ≥3 months | Significantly greater improvements in mean A1C and FPG from baseline to end point in A than B (P<0.0002) Significantly more patients achieved target A1C <7.0% (P<0.0001) and A1C <6.5% (P<0.0033) in Group A than B | Both treatment regimens were well tolerated                                      | -           | Addition of GLIP GITS did not produce any significant or clinically relevant weight gain or changes in BMI                     |
| Feinglos et al., 2002[69]     | GLIP/metformin, 2.5 mg/500 mg (A) or 5 mg/500 mg (B) versus metformin 500 mg (C) | ↓ A1C (A vs. B vs. C): −1.2% versus −0.91% versus −0.19% ↓ FPG (A vs. B vs. C): −2.62 versus −2.34 versus −0.57 mmol/l Proportion of patients achieved A1C <7% (A vs. B vs. C): 75% versus 64% versus 38% (P<0.001) | Mean changes in body weight were ≤1.0 kg                                        | -           | Intensive management with combination therapy improved efficacy at lower doses compared with respective monotherapies, without compromising tolerability |

Contd...
Sulfonylureas versus dipeptidyl peptidase 4 inhibitor as add-on to metformin

SUs compared to dipeptidyl peptidase 4 (DPP-4) inhibitors (DPP-4I) when added to metformin are associated with a significantly greater reduction in A1C from baseline to 12 weeks (mean difference [MD]: 0.21; 95% CI: 0.06, 0.35) but no significant difference at 52 and 104 weeks (MD: 0.06 and 0.02, respectively; 95% CI: −0.03, 0.15 and −0.13, 0.18 respectively). Furthermore, accumulated evidence from 14 RCTs (n > 10,000) reported that SUs were associated with a larger decline in A1C compared to DPP-4I (weighted mean difference [WMD]: 0.08, 95% CI: 0.03, 0.14, P < 0.001). Moreover, a systematic review and meta-analysis reported that GLIM was associated with a 12% greater reduction in A1C compared to DPP-4I (WMD: −0.12; 95% CI: −0.16, −0.07), with a clinically irrelevant weight difference between the treatment (2.1 kg). A 52-week RCT comparing GLIC and vildagliptin as a second-line agent reported a noninferiority of vildagliptin, with a mean change from A1C (−0.85% ± 0.06 vs. −0.81% ± 0.06). Another 52-week RCT also demonstrated noninferiority of saxagliptin versus GLIP; adjusted mean changes from baseline A1C were 0.74% versus 0.80%; the between-group difference was 0.06% (95% CI: −0.05, 0.16). However, in a population-based cohort study in Denmark (4734 patients), A1C reduction with SUs as a second-line agent was better compared to that of DPP-4I (1.2% vs. 0.8%).

Sulfonylureas versus sodium glucose co-transporter 2 inhibitor as add-on to metformin

In a meta-analysis, the combination of metformin plus an SU with the combination of metformin plus a sodium-glucose co-transporter 2 inhibitor (SGLT-2I) was compared. The results supported the combination of metformin plus an SGLT-2I for A1C reduction (pooled between-group difference in A1C of 0.17%; 95% CI: 0.14%–0.20%). In EMPA-REG-H2HSU-trial,
Sulfonylureas versus glucagon-like peptide 1 analogs as add-on to metformin

The dose-dependent variability has been observed in terms of glycemic control between glucagon-like peptide-1 (GLP-1) analogs and SUs when added to metformin. A meta-analysis of several RCTs has found favorable outcomes with the combination of metformin plus SU despite submaximal doses of SUs being compared with maximal doses of daily exenatide (pooled between-group difference in A1C, −0.26%; 95% CI: −0.48%–0.03%). In the LEAD-2 trial, liroglutide reported noninferiority in reduction of A1C compared to GLIM, both added on to metformin. Similarly a 16-week RCT including patients from China, India, and South Korea reported that liroglutide 1.2 and 1.8 mg was noninferior to GLIM (mean A1C reduction: 1.36%, 1.45%, and 1.39%, respectively). However, combination of metformin plus maximum dose of albiglutide (titrated to 50 mg weekly) compared to metformin plus submaximal dose of GLIM (titrated to 4 mg daily) favored the metformin plus albiglutide arm (A1C reduction, −0.9% vs. −0.3%) in HARMONY 3 trial.

Sulfonylureas versus insulin as add-on to metformin

In DiaRegis registry (n = 3810), the addition of insulin reduced the A1C level more as compared to SU after the failure of metformin monotherapy in a duration of 2 years (−0.9 ± 2.0% vs. −0.6 ± 1.4%).

Body weight

SU use is associated with weight gain, a secondary effect that also occurs with insulin, TZD, and glinides. Modern SUs such as GLIM and GLIC MR are associated with weight neutralizing/reducing effect compared to conventional SUs. Furthermore, evidence suggests that GLIM may be the least in the class to endorse weight gain. Nonetheless, weight gain associated with SUs may be due to improved utilization of consumed glucose and a subsequent reduction in glycosuria, thereby indicating reduction in glucotoxicity.

An extra increment in body weight has been observed when SUs were added to ongoing metformin therapy. When compared to TZD, a pooled mean between-group difference of 0.9 kg (95% CI: 0.4–1.3 kg) favored the combination of metformin plus SU. Similarly, the addition of pioglitazone was associated with more weight gain (2.5 kg) than GLIC (1.2 kg) in patients with metformin. Several meta-analyses and RCTs reported that metformin-SU combination was associated with more weight gain compared to metformin-DPP-4I combinations and metformin-SGLT-2I combinations; however, the difference was nonsignificant. Zhang et al. reported that DPP-4I was associated with a reduction in body weight (WMD, −1.652 kg; 95% CI values here as −1.658, −1.646) compared to SUs. Furthermore, in a 16-week prospective study, a variation of weight change has been observed between vildagliptin and GLIC (−0.3 kg vs. +1.4 kg, P = 0.048) after adding to metformin. Similarly, in another trial, canagliflozin 100 and 300 mg and GLIM 6–8 mg/day were associated with −4.1%, −4.2%, and 0.9% reductions in body weight, respectively. Furthermore, several RCTs reported a weight loss in patients with the combination of metformin and GLP-1 receptor agonists and weight gain in patients with the combination of metformin and SUs. Compared to insulin, in BETA trial, addition of GLIM to metformin produced a less weight gain (mean between-group difference in weight of −1.7 kg, P = 0.02) in patients with T2DM. In DiaRegis registry (n = 3810), the addition of insulin also reported increment of body weight from baseline as compared to SU after the failure of metformin monotherapy in a duration of 2 years (+0.8 ± 9.0 vs. −0.4 ± 4.8 kg).

Safety and tolerability

Hypoglycemia is a primary clinical concern during the intensification of the antidiabetic regimen in patients with T2DM. The hypoglycemic potentials of SUs are different pertaining to their variable mode of action and pharmacokinetic and pharmacodynamic properties. Evidence suggests that modern SUs are associated with less risk of hypoglycemia compared to conventional SUs. Furthermore, the European GUIDE (GIUcose control in type 2 diabetes: Diamicon MR vs. GLIM) study (n = 845) was the first double-blind, 27-week, parallel-group, large-scale, head-to-head study compared once-daily GLIC MR (maximum dose up to 120 mg) to once-daily GLIM (maximum dose up to 6 mg) either as monotherapy or in combination. Hypoglycemia occurred significantly lesser with GLIM MR compared to GLIM (3.7% vs. 8.9%, respectively, P = 0.003), though a higher number of patients reached A1C <6.5% with GLIM (17% vs. 2%) which may influence the hypoglycemic episodes. Moreover, no episodes of severe hypoglycemia were reported during the study in patients, reiterating the safety of both these modern SUs.

Kim et al. in their randomized, open-label, parallel group, multicentric study reported that patients with GLIM/metformin combination therapy experienced more hypoglycemia compared with metformin uptitration therapy (41% vs. 5.6%, P < 0.0001), but there was no serious hypoglycemia reported in any group. In a 52-week RCT, patients taking GLIC or vildagliptin experienced similar incidence of any adverse events (−61%); however, GLIC patients had more serious adverse events (8.7% vs. 6.7%) and more vildagliptin patients discontinued as a result of an unsatisfactory effect (n = 22 vs. 13).

Evidence shows an increase in hypoglycemia risk with SUs compared to other OADs when added to metformin monotherapy. The hypoglycemic risk, when compared with
SU (0.53; 95% CI: 0.32–0.87) compared with SUs.\[90\]

Several RCTs reported that the rate of genital and urinary tract infections was more common with SGLT-2I compared to SUs.\[92,99\] Furthermore, there were increased odds of genital infections for metformin plus SGLT-2I and differences in relative odds by gender were as follows: pooled OR: 5.2 (95% CI: 3.4–7.8) for women and pooled OR: 7.6 (95% CI: 4.0–14.4) for men.\[99\] Moreover, volume depletion was observed frequently with canagliflozin than GLIM.\[92\] Similarly, gastrointestinal events with liraglutide and exenatide were more commonly reported.

In a retrospective cohort study, 20,070 patients were newly treated with an SU, DPP-4I, or a TZD following metformin therapy failure. It was reported that the therapy failure at 1 year was 15% with SU, 23% with DPP-4I, and 8% with TZD.\[101\] Furthermore, multivariate analysis of the data showed that addition of a DPP-4I was associated with an increased risk of treatment failure (adjusted hazard ratio (aHR): 1.58; 95% CI: 1.48–1.68) compared to the SU group, while adding a TZD was associated with a adjusted hazard ratio (aHR: 0.45; 95% CI: 0.41–0.50).

Moreover, choice of drugs should be based on the risk of hypoglycemia in an individual patient; further details regarding this are provided in patient and dose selection sections in this article.

All-cause mortality and macrovascular complications

A meta-analysis including several RCTs demonstrated that SUs (GLIB, GLIP, GLIC, and GLIM) as an add-on to metformin were not associated with all-cause mortality (OR: 1.26; 95% CI: 0.94–1.68; \( F = 0\% \)) and CV mortality (OR: 1.40; 95% CI: 0.61–3.22; \( F = 6\% \)). Furthermore, among all SUs, GLIP was associated with increased all-cause and CV mortality, while the risk was least with GLIM (numerically, though did not achieve statistical significance).\[91\] Modern SUs show less CV mortality than conventional SUs due to more pancreatic selectivity action. A randomized, double-blind, crossover study of GLIC 80 mg twice daily and GLIM 2 mg once daily, each for 4 weeks as add-on therapy to metformin, found no evidence between SUR1-specific (GLIC) and nonspecific SU (GLIM) in differential effects on arterial distensibility, endothelial function, or vasodilator mechanisms.\[102\]

Metformin remains an ideal first-line agent and among the SUs, the relative safety of a GLIC makes it a preferred SU. In a population-based study on 107,806 patients from the Danish registry with a median follow-up of 3.3 years, Schramm et al. evaluated several mortality end points with different insulin secretagogues compared with metformin in patients with or without a previous history of myocardial infarction (MI).\[103\] The all-cause mortality was significantly higher with all SUs (GLIM: HR: 1.32, 95% CI: 1.24–1.40; GLIP: HR: 1.27, 95% CI: 1.17–1.38; and GLIB: HR: 1.19, 95% CI: 1.11–1.28) except GLIC (HR: 1.05, 95% CI: 0.94–1.16) in patients with a previous history of MI. Similar significant increase in all-cause mortality was observed with all SUs except GLIC in those with a previous history of MI. Furthermore, this was a retrospective study and therefore there is a likelihood of selection bias (patients on GLIM had a higher baseline risk and likely contributed to more morbidity and mortality). In another nationwide study on 202,272 Danish patients, GLIP, GLIB, GLIM, and TOLB appeared to be associated with an increased risk compared with GLIC when used in combination with metformin.\[104\]

When added to metformin, pioglitazone found to produce potential benefits in terms of improvements in specific lipid abnormalities compared to GLIC or GLIM.\[74,89,105\] Nonetheless, a single retrospective cohort study from a Veterans Affairs population with Medicare (\( n = 80,936 \)) found a nonsignificant increase in the risk of stroke or MI (composite outcome) for SU-based versus TZD-based therapy: aHR: 1.15 (95% CI: 0.8–1.66; \( P = 0.46 \)).\[106\] The pooled OR from five RCTs on mortality between DPP-4I and SUs, when added on to metformin, was 0.64 (95% CI: 0.27–1.51).\[99\] In the Danish National Registry, combination therapies with incretin-based drugs and metformin were compared with a combination of metformin and SU in T2DM for all-cause mortality, CV mortality, and combined end point of MI, stroke, and CV mortality. By keeping metformin + SU as a reference, the study demonstrated a significantly decreased risk of death among metformin plus DPP-4I users (\( n = 11,138 \)) with a relative risk (RR) of 0.65 (0.54–0.80) for mortality, 0.57 (0.40–0.80) for CV mortality, and 0.70 (0.57–0.85) for the combined end point. For metformin + GLP-1 receptor agonist, the RR for mortality was 0.77 (0.51–1.17), for CV mortality was 0.89 (0.47–1.68), and for the combined end point was 0.82 (0.55–1.21).\[104\] However, a meta-analysis suggested that long-term all-cause mortality (which was low [<1%] across studies) was similar for metformin plus SGLT-2I and metformin plus SU (pooled OR: 0.86; 95% CI: 0.29–2.55).\[91\] Moreover, a significant reduction in urine albumin was observed in the metformin plus exenatide arm (37.97%) compared to the metformin plus GLIM arm (5.76%).\[107\]

Nonetheless, in a meta-analysis of 301 clinical trials which utilized the glucose-lowering drugs including metformin, SUs, TZD, DPP-4I, alpha-glucosidase inhibitor (AGI), SGLT-2I, GLP-1 receptor agonists, meglitinides, and insulin either alone or in combination suggested no significant difference in the risk of CV mortality between the antiobiotic drugs.\[108\]

A summary of landmark trials comparing outcomes of SUs with other antidiabetic drugs as add-on therapy is summarized in Table 8.
**Table 8: Summary of landmark trials comparing outcomes of sulfonylureas in combination with other antidiabetic drugs**

| Study        | Interventions                                      | Glycemic efficacy                                      | Adverse events                        | Weight gain             | Conclusion                                                                 |
|--------------|----------------------------------------------------|--------------------------------------------------------|---------------------------------------|-------------------------|----------------------------------------------------------------------------|
| COMO6[90]    | Pioglitazone + metformin/SU (A) versus FDC of metformin and GLIB (B) | ↓ A1C (A vs. B): 1.11% versus 1.29% (P<0.0192) | Confirmed/severe hypoglycemia (A vs. B): 1.1% versus 15.3%; P<0.0001 | Co administration of pioglitazone with metformin or an SU is an effective alternative for patients with T2DM |
| GENERATION[100] | Saxaglptin (A) or GLIM (B) added to metformin       | Achievement of A1C <7% (A vs. B): 37.9% versus 38.2% (P=0.9415) | | | Saxaglptin was numerically (not significantly) superior to GLIM for patients aged <75 years numerically inferior for patients aged ≥75 years |
| CANTATA-SU[82] | Metformin + GLIM versus metformin + canagliflozin 100 mg and 300 mg | Canagliflozin 100 mg was noninferior to GLIM (0.01% [95% CI: 0.11-0.09]), and canagliflozin 300 mg was superior to GLIM (0.12% [0.22-0.02]) | More genital mycotic infections, urinary tract infections, and osmotic diuresis-related events observed with canagliflozin | | Canagliflozin provides greater A1C reduction than does GLIM and is well tolerated in patients with T2DM receiving metformin |
| EMPA-REG-H2HSU[81] | Metformin + GLIM (A) versus metformin + empagliflozin (B) | Change in A1C from baseline with empagliflozin versus GLIM was 0.11% (95% CI: 0.19-0.02; P=0.0153 for superiority) | Serious adverse events: A: 11%; B: 16% Confirmed hypoglycemic events A: 24%; B: 2% | | Empagliflozin might serve as an effective and a well-tolerated second-line treatment option for patients with T2DM who have not achieved good glycemic control on metformin |
| LEAD-2[84] | Metformin + GLIM (A) versus metformin + liraglutide (B) and metformin (C) | ↓ A1C: A, 0.5%; B, 0.6%; C, 0.3% | Minor hypoglycemia (A vs. B): 24% versus <5% (P<0.0001) | Significant weight loss with liraglutide compared with GLIM (P<0.0001) | Liraglutide provided sustained glycemic control over 2 years comparable to that provided by GLIM |
| BETA[99] | Metformin + GLIM (A) versus metformin + glargine (B) | A1C and FPG significantly in each group but not different between two groups | No severe hypoglycemia: symptomatic hypoglycemia more frequent with GLIM (P=0.01) | Less weight gain was observed in the GLIM group | Glargine and GLIM can be considered after failure of metformin monotherapy |
| EUREXA[100] | Metformin + GLIM (A) versus metformin + exenatide + (B) | Attainment of HbA1c <7% (A vs. B): 31% versus 44% (P<0.0001); Attainment of HbA1c ≤6.5% (A vs. B): 18% versus 29% (P<0.0001) | Hypoglycemia (P<0.0001) higher in GLIM and GI adverse events was significantly higher (P=0.0005) in the exenatide group | Significantly greater decrease in body weight in patients given exenatide than in those given GLIM (P<0.0001) | These findings provide evidence for the benefits of exenatide versus GLIM for control of glycemic deterioration in patients with type-2 diabetes inadequately controlled by metformin alone |

BMI: Body mass index, FDC: Fixed-dose combination, FPG: Fasting plasma glucose, SU: Sulfonylurea, T2DM: Type 2 diabetes mellitus, GLIB: Glibenclamide, GLIM: Glimepiride, CI: Confidence interval, A1C: Glycated hemoglobin, GI: Gastrointestinal, HbA1c: Hemoglobin A1c, ↓: decrease

**Sulfonylurea + other oral antidiabetic drugs**

**Mechanism**

In patients with inadequate glycemic control on SUs, there are a number of OADs available which can be used in combination with an SU. However, the choice of therapy should be individualized based on patient characteristics, preferences, and cost. TZDs decrease insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Thus, the combination of SUs and TZD may be beneficial for supporting each other in T2DM.

DPP-4 inhibitors elevate cellular cyclic adenosine monophosphate (cAMP) levels in pancreatic β-cells, leading to potentiated insulin secretion. SUs mimic the glucose-induced K<sub>ATP</sub> channel-dependant pathway. Therefore, an increase in cAMP induced by incretin therapy potentiates K<sub>ATP</sub> channel-independent insulinotropic action by glucose.[111-113] Therefore, SUs and DPP-4I may be an effective combination for supporting inappropriate insulin secretion in T2DM;
however, careful consideration is required when initiated in the elderly and/or patients with renal insufficiency.\(^{[113]}\)

**Glycemic efficacy**

A combination therapy with SU and TZD resulted in remarkable glycemic control when compared to each monotherapy. A randomized, double-blind, placebo-controlled, multicentric study comparing the efficacy of add-on of GLIM to on-going rosiglitazone reported that combination therapy with GLIM produced greater reductions in A1C (mean [standard error (SE)]: −1.2% [0.1%] vs. −0.3% [0.2%]; \(P<0.001\)) and FPG (mean [SE]: −24.4 [6.0] mg/dL vs. 5.9 [8.0] mg/dL; \(P<0.006\)).\(^{[114]}\)

Similarly a 28-week, double-blind, parallel-group RCT revealed that GLIM/rosiglitazone FDC significantly reduced A1C (2.5 ± 1.4%) than rosiglitazone (1.8 ± 1.5%) or GLIM (1.7 ± 1.4%) monotherapy (model-adjusted mean treatment difference, \(P<0.0001\) vs. both rosiglitazone and GLIM).\(^{[115]}\) Evidence suggests that treatment with a combination of pioglitazone and SUs provided extensive glycemic control as compared to baseline glycemic level; however, no significant difference was found when compared to metformin and SU-based combinations.\(^{[89,109,116]}\)

In a multicentric, prospective, randomized, open-label study, patients who had an uncontrolled glycemic level with sitagliptin and low-dose GLIM were randomized to receive up titration with either sitagliptin or GLIM. There was no significant difference in the A1C-lowering effects between the two groups. However, a significant A1C-lowering effect from baseline of GLIM up titration was found (\(P<0.01\) vs. baseline).\(^{[117]}\) Furthermore in a 52-week, prospective, single-arm study, sitagliptin and low-dose GLIC or GLIM also reduced A1C by −0.80% (95% CI: −0.90 to −0.68) (\(P<0.001\)) from baseline.\(^{[118]}\)

In conditions where dual therapy failed to obtain optimal glycemic control, the addition of a third agent (SUs) could be helpful in achieving glycemic targets. GLIM as an add-on to metformin and TZD resulted in significant improvement in A1C level (mean [SE]: −1.31% [0.08] vs. −0.33% [0.08], respectively; \(P<0.001\)) from baseline with more patients achieving target A1C ≤ 7% compared with metformin and TZD combination (62.2% vs. 26.0%, \(P<0.001\)).\(^{[119]}\) Evidence suggests that GLIM strongly enhances the glucose-lowering effect in triple oral antidiabetic therapy with sitagliptin and metformin for patients with T2DM.\(^{[120]}\)

A systematic review and network meta-analysis evaluated the efficacy of triple therapy regimen for T2DM. The study included SUs in all combinations except one (MET + TZD + DPP-4I). For A1C reduction, all triple therapies were statistically superior to MET + SU dual therapy. However, none of the triple therapy combinations demonstrated differences in A1C compared with other triple therapies.\(^{[121]}\)

**Body weight**

In a randomized, double-blind, placebo-controlled, multicentric study at the end of the 1\(^{st}\) year, GLIM with pioglitazone (4.9%) and GLIM with rosiglitazone (6.2%) treatment groups had significant increases from baseline in body mass index (BMI) (\(P<0.05\)).\(^{[122]}\) Furthermore, when added to GLIC, pioglitazone resulted in an increment of body weight in comparison to metformin (3.7 vs. −1.7 kg).\(^{[99]}\) However, in a 52-week, prospective, single-arm study, sitagliptin and low-dose GLIC or GLIM reduced BMI by −0.38 kg/m\(^2\) (95% CI: −0.72, −0.04) (\(P<0.05\)) from baseline.\(^{[118]}\)

In a prospective observational study, no change in body weight (69.6 ± 3.0–69.1 ± 2.9 kg in the low-dose group and 62.1 ± 2.6–61.9 ± 3.0 kg in the high-dose group; \(P>0.05\) for both groups) was observed in patients taking combination of 50 mg/day sitagliptin and low-dose GLIM (2 or 3 mg decreased to 1 mg: \(n=15\)) compared to high-dose GLIM (4 or 6 mg decreased to 1 mg).\(^{[111]}\)

**Safety and tolerability**

Evidence suggests that the combination regimens of SU and TZD were well tolerated by the patients with no significant difference in adverse effects with the comparators.\(^{[114,115,117,125]}\)

Furthermore, no hypoglycemic episodes were reported by various studies assessing the efficacy of sitagliptin and SU combinations.\(^{[111,124]}\) Moreover, several studies reported that the combination treatments with sitagliptin and SU were safe and well tolerated in patients with T2DM.\(^{[111,117,118]}\)

In a 30-week, randomized, double-blind, placebo-controlled, parallel-group study, the risk of hypoglycemia (51.2% vs. 8.3%, \(P<0.001\)) was greater with GLIM add-on to metformin-TZD than placebo.\(^{[119]}\) Similarly, in EUREXA trial, the ratio of documented symptomatic (blood glucose ≤70 mg/dL [3.9 mmol/L]) hypoglycemic rates for add-on GLIM to add-on TZD was 8.48 (\(P<0.0001\)).\(^{[125]}\)

**All-cause mortality and macrovascular complications**

The increase of lipid risk factors for CV diseases (CVDs) from baseline was more significant in GLIM-rosiglitazone patients compared to GLIM-pioglitazone patients.\(^{[122,126]}\) In an Indian RCT, FDC containing GLIM (2 mg), pioglitazone (15 mg), and metformin sustained release (500 mg) significantly reduced the levels of triglyceride, low-density lipoprotein cholesterol, and total cholesterol.\(^{[127]}\)

A summary of published RCTs comparing combinations of SUs and other OADs in the management of T2DM is shown in Table 9.

**Sulfonylurea + insulin**

**Mechanism**

SUs when added to insulin increase endogenous insulin secretion and possibly exert some extra pancreatic actions on muscle and liver, thereby improving glycemic control and decreasing daily insulin requirements.\(^{[128]}\) A subset of T2DM patients who are mild to moderately obese, have adequate endogenous insulin secretory reserve, and are in poor glycemic regulation (A1C >10%), despite twice-daily insulin administration, may show significant improvement in glycemic regulation and/or decrease in insulin daily dose of
Table 9: A summary of published randomized controlled trials comparing sulfonylureas and other oral antidiabetic drugs in the management of type 2 diabetes mellitus

| Author et al., 2004 | Interventions | Glycemic efficacy | Adverse events | Weight change | Conclusion |
|--------------------|---------------|-------------------|----------------|---------------|------------|
| Pioglitazone + GLIM (A) versus rosiglitazone + GLIM (B) | No significant differences were found between treatment groups after 1 year | - | Both groups experienced significant ↑ BMI (P<0.05) | Both combinations of significantly improved glycemic control in the study patients |
| Shimoda et al., 2014 | Dose up with sitagliptin (50 mg/day) and GLIM (<2 mg/day): 50 mg/day sitagliptin (A) or 0.5 mg/day GLIM (B) | Changes in A1C between the two groups were not significant (P=0.13) A1C ↓ significantly by Group B (P<0.01 vs. baseline), but not by Group A (P=0.74) | No clinically significant adverse events, except for hypoglycemia | - | A significant A1C-lowering effect from baseline of GLIM dose-up was found |
| Umeyahara et al., 2014 | Three treatment groups: Reduced doses of GLIM (0.5 mg/day, 1 mg/day, or 2 mg/day) in addition to sitagliptin for 24 weeks | Despite dose reduction of GLIM, combination therapy with sitagliptin induced significant improvements in A1C levels (0.8%, P<0.001) | No symptomatic hypoglycemia was documented | No changes in body weight | Sitagliptin and low-dose GLIM (0.5 mg/day) combination is effective and safe in Japanese patients with uncontrolled T2DM |
| Comaschi et al., 2007 | Pioglitazone + metformin/SU versus FDC of metformin and GLIM (B) for 6 months | Pioglitazone and FDC resulted in similar ↓ A1C (1.11% vs. 1.29%, respectively; P=0.192) and FPG (2.13 vs. 1.81 mmol/L, respectively; P=0.370) | - | - | Co-administration of pioglitazone with metformin or an SU is an effective alternative for patients with T2DM |
| Charbonnel et al., 2005 | Pioglitazone + GLIC (A) or pioglitazone + metformin (B) for 2 years | No significant differences in changes from baseline in glycemic parameters A versus B | Pioglitazone caused greater ↓ in triglycerides and ↑ in HDL than comparators (P<0.001) | ↑ body weight (A vs. B): 3.7 versus 1.7 kg | As add-on therapy to existing SU/metformin, pioglitazone improved glycemic control and this improvement was sustained over 2 years |
| Hanefeld et al., 2004 | Pioglitazone + SU (A) or metformin + SU (B) for 1 year | No significant between treatment differences in A1C, FPG, fasting insulin level | Both combinations were well tolerated with no evidence of hepatic or cardiac toxicity in either group | - | SU plus pioglitazone is an effective and well-tolerated combination regimen that may provide additional beneficial effects for patients with T2DM |

| Author et al., 2005 | Interventions | Glycemic efficacy | Adverse events | Conclusion |
|--------------------|---------------|-------------------|----------------|------------|
| GLIM + metformin + rosiglitazone or pioglitazone (A) versus placebo (B) | Significantly improved at end point with Group A versus B (mean [SE], 1.31% [0.08] vs. 0.33% [0.08]; P<0.001) Attainment of A1C ≤7% (A vs. B): 62.2 versus 26.0%; P<0.001 between groups | Hypoglycemia (A vs. B): 51.2 versus 8.3%; P<0.001 | Mean change in weight (A vs. B): (3.76 [0.54] versus 0.45 [0.52] kg; P<0.001) | Uncontrolled T2DM patients with dual therapy (metformin and a thiazolidinedione), the addition of GLIM ↑ glycemic control with an acceptable tolerability profile |
| Arai et al., 2013 | GLIM + metformin + sitagliptin (A) versus metformin + sitagliptin (B) | Significantly greater changes were observed in A1C and glycated albumin levels in both groups during the 2-3 months’ period than in the 1-3 months’ period | - | - | GLIM is important for good glycemic control in triple therapy with sitagliptin and metformin |
| Schernthaner et al., 2015 | Metformin + exenatide + GLIM (A) versus metformin + exenatide + thiazolidinedione (B) | A1C: Significantly better with B versus A: 130-week difference 0.48% (95% CI: 0.19, 0.77) | Ratio of documented symptomatic hypoglycemia rates (A to B): 8.48 (P<0.0001) | Significantly BMI and systolic blood pressure in Group B | Thiazolidinedione was an effective and well-tolerated third-line therapy in patients with uncontrolled hyperglycemia after long-term therapy of metformin and exenatide BID |

GLIM: Glimepiride, SUs: Sulfonylureas, A1C: Glycated hemoglobin, BMI: Body mass index, FDC: Fixed-dose combinations, FPG: Fasting plasma glucose, HDL: High-density lipoprotein, SE: Standard error, SU: Sulfonylurea, T2DM: Type 2 diabetes mellitus, BID: Twice daily, ↓: decreased/decrease in/decrease, ↑: increase/increase
Evidence suggests that addition of SUs to insulin in patients with uncontrolled glycemic levels reduces the insulin dose by 20%–30% and avoids hypoglycemia. Therefore, studies have compared the treatments with smaller insulin dose with SU and a larger insulin dose without SU. A summary of published RCTs comparing combinations of SUs and insulin in the management of T2DM is shown in Table 10.

### Table 10: A summary of published randomized controlled trials comparing sulfonylureas and insulin in the management of type 2 diabetes mellitus

| Author | Interventions | Glycemic efficacy | Adverse events | Weight gain | Conclusion |
|--------|--------------|-------------------|----------------|-------------|------------|
| **Basal insulin + sulphonylureas** |
| Zhou et al., 2015[131] | Glargine + GLIC MR versus premix insulin monotherapy | Combination therapy showed a significantly more robust A1C ↓ (P=0.0308) | Rates of hypoglycemic episodes were similar - | - | Patients with uncontrolled T2DM with OADs attained greater benefit from OD insulin glargine plus GLIC MR regimen than from a BID premixed insulin |
| Schiel et al., 2008[132] | Group A: OD morning glargine + GLIM; Group B: Glargine + GLIM and metformin | Group C: premixed insulin | A1C ↓ significantly from baseline in Groups A and B, but not in Group C; (A: −0.35%, P=0.013; B: −0.69%, P=0.0057; C: −0.0057; P=0.32) | Symptomatic hypoglycemia (mean events/patient: Group A, 2.2; Group B, 2.3; Group C, 2.0) | - | Switching from premixed insulin to insulin glargine plus OAD treatment resulted in similar glycemic control and treatment satisfaction |
| Janka et al., 2007[133] | OD morning glargine with continued OADs (GLIM + metformin) (A) or BID premix insulin 70/30 alone (B) | FBG ↓ significantly more with Group A (−57 mg/dL) than Group B (−40 mg/dL) (P=0.002) | Episodes of any hypoglycemia (A vs. B): 3.68/patient-year versus 9.09/patient-year (P=0.008) | Mean weight gain (A vs. B): 1.3±3.0 versus 2.2±3.9 kg (P=0.17) | In elderly patients, addition of OD morning glargine + OAD is a simple regimen to initiate insulin therapy, restoring glycemic control more effectively and with less hypoglycemia than BID 70/30 alone |
| Standl et al., 2005[134] | Morning glargine + GLIM (A) versus bedtime glargine (B) for 24 weeks to titrate to target FBG ≤100 mg/dL | No significant difference in change in glycemic parameter, insulin dose, and attainment of A1C <7% between groups | No clinically relevant between-treatment differences | - | Flexible dosing with simple GLIM/glargine regimens achieved significant and practically meaningful improvements in glycemic control |
| Olsson and Lindström, 2002[135] | Bedtime NPH insulin + daytime SU (A) versus insulin BID group (BID premixed combination of regular human and NPH insulin [B]) | No significant difference in change in A1C from baseline between groups (P=0.03; NS between treatment groups) | No significant difference in change in body weight between groups (NS; P=0.02 between groups) | - | Combination therapy is an attractive alternative when starting insulin treatment in T2DM patients |
| Park et al., 2014[136] | Glargine + metformin (A) versus glargine + GLIM (B) versus glargine + metformin + GLIM (C) | The ↓ in A1C was more pronounced with group C than Groups A and B (overall P=0.02) | Hypoglycemia risk of any type did not significantly differ between groups | Weight gain did not significantly differ among the groups | The combination of metformin and GLIM+glargine resulted in a significant improvement in overall glycemic control as compared with the other combinations |

| **Premix insulin + sulphonylureas** |
| Li et al., 2014[137] | GLIM-added Group (A) or the insulin-increasing Group (B) while continuing current insulin-based therapy | Insulin doses were significantly ↓, and the mean A1C, FBG, and P2BG were improved greater in the Group A compared with Group B | Body weight ↑ significantly in Group B (P<0.05); no significant change in Group A (P>0.05) | - | Adding GLIM to current insulin treatment led to glycemic control with a significant smaller daily insulin dose |

FBG: Fasting blood glucose, MR: Modified release, NPH: Neutral Protamine Hagedorn, NS: Nonsignificant, OD: Once daily, OAD: Oral antidiabetic drugs, P2BG: 2 h postprandial blood glucose, SU: Sulfonylurea, T2DM: Type 2 diabetes mellitus, GLIC: Gliclazide, A1C: Glycated hemoglobin, BID: Twice daily, ↑: increase, ↓: decrease/decreased/decrease in
**Glycemic efficacy**

In a Cochrane systematic review including nine trials (316 patients), insulin-SU combination therapy compared with insulin monotherapy was associated with a reduction of A1C; MD of $-1\%$ (95% CI: $-1.6$ to $-0.5$; $P < 0.01$). However, insulin-metformin ($-0.9\%$), insulin-AGIs ($-0.4\%$), and insulin-DPP4I ($-0.4\%$) combinations had revealed a less significant change in A1C compared to insulin-SU combination therapy. Furthermore, a meta-analysis comprising 17 RCTs reported a significantly lower A1C in SU groups (in combination with insulin) compared with placebo (0.46% lower; 95% CI: 0.24, 0.69, $F = 43.6\%$). Moreover, another meta-analysis also found favorable outcomes with insulin-SU combination therapy in terms of glycemic control compared to insulin monotherapy ($P < 0.0001$).

Past studies show that approximately half of the patients attain A1C <7% with dual insulin therapy whereas patients taking insulin alone met goals only one-third of the time. Yki-Järvinen et al. determined that a basal insulin regimen containing GLIM decreased total daily insulin requirements by approximately one-third. A combination of once-daily basal insulin with an SU versus monotherapy with premixed insulin has proven to decrease total insulin dose by the same factor.

A Korean RCT after 24 weeks of observation period reported a pronounced reduction of A1C with the addition of GLIM to insulin glargine and metformin than insulin glargine plus metformin (0.49% [95% CI: 0.16%−0.82%], $P = 0.005$).

In “4-T” trial, patients with uncontrolled glycemic level with SUs and metformin were randomized to receive twice-daily biphasic insulin aspart 30 or thrice-daily prandial insulin aspart, or once-daily (twice if required) basal insulin detemir. After 1-year follow-up, the mean reduction in A1C was significantly greater in the biphasic (1.3%) and prandial groups (1.4%) than in the basal group (0.8%). However, after 3 years, basal or prandial insulin-based regimen had better A1C control than biphasic insulin-based regimen.

**Safety tolerability and body weight**

The combination of insulin and SU results in a reduction of necessary insulin dose per day. However, most studies adding SUs to insulin reported milder hypoglycemic episodes versus insulin monotherapy (range: 2.2−6.1 vs. 2.0−2.6 episodes per participant). The addition of SUs into insulin monotherapy resulted in an additional weight gain of 0.4 to 1.9 kg versus $-0.8$ to 2.1 kg in the insulin monotherapy group. However, no change in body weight was observed by addition of SUs to insulin in several older RCTs.

**Role of Sulfonylureas in Combination**

**Cost**

Medication cost always plays a significant role in the management of any disease in underdeveloped and developing countries, as it directly affects the drug utilization and patient compliance. Patients without any medical insurance and below the poverty line encounter numerous challenges for the use of expensive medicines in the management of T2DM. A study revealed that the medication cost for diabetes was USD 138 per patient per year which is equivalent to 8.1% of the total budgeted health expenditure for that financial year in sub-Saharan Africa. However, SUs are associated with a significantly lower cost per quality-adjusted-life-years (QALYs) and result in the longest time to insulin dependence. Sensitivity analysis on the medication cost reported the difference in the expected medication cost per QALY from the base-case cost; metformin costs 81.75 USD/month, SU costs 54.85 USD/month, DPP-4I costs 232.84 USD/month, GLP-1 receptor agonist costs 325.97 USD/month, and insulin therapy costs 245.70 USD/month. This cost comparison indicates that SUs should be preferred as an add-on to metformin if the choice of drug is based on cost. Furthermore, FDC users on an average had higher out-of-pocket costs for their prescriptions and had a less restricted heath plan. In summary, lower cost without compromising the glycemic efficacy and tolerability could make SUs the prime choice of treatment of T2DM.

**Adherence**

Medication compliance is directly related to the cost, availability, dosage regimen, and complications associated with the treatment. In the current scenario, FDCs increase the patient compliance by reducing the frequency of drug administration and cost of the medication. Pan F et al. reported that the FDC of metformin-glyburide resulted in 13% increase in patient adherence ($P < 0.001$) compared to the 2-pill regimen. Similarly, a meta-analysis also reported that FDC decreases the risk of medication noncompliance, improves clinical outcomes, and should be considered in patients with chronic conditions.

**Fixed-dose combinations**

Combining two or three antihyperglycemic agents with complementary mechanisms of action is a cornerstone of T2DM management. Apart from that, low-dose combination therapy compared to high-dose monotherapy might exhibit lesser side effects and can achieve similar or better glycemic control. Furthermore, FDCs reduce number, frequency, and flexibility of dosage administration and minimize the treatment complexity, thereby improving patient adherence. In a meta-analysis, use of FDCs with antihyperglycemic agents was associated with lower A1C and higher mean possession ratio values compared to dual therapies in patients with T2DM. Furthermore, a systematic review suggested that T2DM patients treated with FDC therapy may have better adherence, improved satisfaction, and lower direct medical costs, compared to those treated with loose pill combination therapy. A list of available SUs either individually or in FDCs with their strength, dose, and required dose titration is summarized in Table 11.
Table 11: A list of sulfonylurea monotherapy and fixed-dose combinations of sulfonylureas with available strength, recommended dose, and dose titration

| SUs         | Strengths available (mg) | Recommended dose | Dose titration                                                                 |
|-------------|--------------------------|------------------|--------------------------------------------------------------------------------|
| **Monotherapy** |                          |                  |                                                                                 |
| GLIB        | Tablet: 1.25, 2.5, 5      | With breakfast or first main meal | Adult: No >2.5 mg/day at weekly intervals                                        |
|             | Micronized tablet: 1.25, 2.5, 5, 6 |       | Adult micro: No >1.5 mg/day at weekly intervals                                  |
|             |                           |                  | Geriatric: 1.25-2.5 mg daily                                                   |
| GLIC        | Tablet: 40, 80           | Adults: 40-80 mg daily in the morning | Increased if necessary up to 320 mg (4 tablets) daily                           |
| GLIC MR/XR  | Tablet: 30, 60           | 30-120 mg at breakfast | Daily dose of MR not to exceed 120 mg                                           |
| GLIP        | IR: 5, 10                | Before breakfast  | Adult IR: 2.5-5 mg as frequently as every few days                             |
|             | ER: 2.5, 5, 10           | Adult: 5 mg daily  | Adult ER: Adjustments no more frequently than every 7 days                     |
|             |                           | Geriatric: 2.5 mg daily | Geriatric IR: 2.5-5 mg every 1-2 weeks as needed                                 |
|             |                           |                  | Geriatric ER: Conservative titration                                           |
| GLIM        | 0.5, 1, 2, 3, 4, 6       | With breakfast or the first main meal | Adult: 1-2 mg every 1-2 weeks as needed                                         |
|             |                           | Adult: 1-2 mg daily | Geriatric: Conservative titration                                              |
|             |                           | Geriatric: 1 mg daily | Renal: Conservative titration                                                  |
| TOLB        | 500, 1000                | Initial dose: 1-2 g daily | The initial and maintenance dosing should be conservative to avoid hypoglycemic reactions in elderly, debilitated, or malnourished patients, and patients with impaired renal or hepatic function |
|             |                           | Maintenance dose: 0.25-3 g orally | Total daily dose may be taken either in the morning or in divided doses through the day |
| Gliquidone  | 30                       | Initial dose: 15 mg/day taken before breakfast; may increase slowly | It is contraindicated in renal failure, liver diseases, diabetic coma, and type 1 diabetes |
|             |                           | Usual: 45-60 mg/day in divided doses |                                                                                 |
| **FDC**     |                          |                  |                                                                                 |
| GLIB + metformin | 1.25/250, 2.5/500, 5/500, 2.5/400 | With meals Adults: Starting dose: 1.25/250 mg or 5/500 mg orally once or twice a day | Maximum dose: 20 mg-2000 mg/day |
| GLIB + metformin + pioglitazone | 5/500/7.5, 5/500/15 | Both strengths can be prescribed once or twice a day as per physician’s recommendation | As with individual agents |
| GLIC + metformin | 30/500, 60/500, 80/500 30 (MR)/500 (ER), 60 (MR)/500 (ER) | With meals As with individual agents | Maximum dose: 20 mg/2000 mg/day |
| GLIC + metformin + pioglitazone | 60/500/7.5, 60/500/15 | With meals As with individual agents | Contraindicated in pediatrics |
| GLIP + metformin | 2.5/500, 5/500          | With meals Starting dose: 2.5-5/250 mg orally once or twice a day | Maximum dose: 20 mg-2000 mg/day |
| GLIM + metformin | 0.5/500, 1/500, 2/500, 1/850, 2/850, 3/850, 1/1000, 2/1000, 4/1000 | With meals | As with individual agents |
| GLIM + pioglitazone | 1/15, 2/15, 2/30, 4/30, 4/45 | With the first main meal Initial dose: 2-4/30 mg OD | As with individual agents |
| GLIM + metformin + pioglitazone | 1/500/15, 2/500/15 | Both strengths can be prescribed once or twice a day as per physicians recommendation | As with individual agents |
| GLIM + metformin + voglibose | 1/500/0.2, 2/500/0.2, 1/500/0.3, 2/500/0.3 | With the first main meal | All are as per physician’s recommendation |
|             |                           | 1/500/0.2 mg is recommended OD; 2/500/0.2 mg is recommended once or twice a day | As with individual agents |
|             |                           | 2/500/0.3 recommended BID | As with individual agents |

MR: Modified release, IR: Immediate release, ER/XR: Extended release, GLIB: Glibenclamide, GLIC: Gliclazide, GLIP: Glipizide, GLIM: Glimepiride, TOLB: Tolbutamide, SU: Sulfonylurea, BID: Twice daily, OD: Once daily
**Elderly**

SUs are usually well tolerated; however, mild hypoglycemia has been reported with long-acting SUs (e.g., CHOL, glyburide). For older patients who have persistent hyperglycemia with lifestyle intervention and metformin, the addition of a short-acting SU such as GLIP is a preferred option. A double-blind randomized and open-label comparative study after 2 years of treatment concluded that GLIC MR in combination with other OADs significantly improved glycemic control in the elderly and renal-impaired T2DM patients with a very good safety profile.[159] A recent review evaluated the comparative safety and efficacy of commonly available SUs (GLIB, GLIC, GLIM, and GLIP) for the management of T2DM in older patients.[160] The study reported that GLIC can be used in older patients due to its low risk of hypoglycemia; however, it is suggested to restrict the use of GLIB in such populations. Furthermore, several guidelines including IDF and Canadian guidelines also recommend modern SUs (GLIC MR and GLIM) as a drug of choice for elderly T2DM patients.[161,162] In GENERATION trial, a similar proportion of patients achieved the primary end point of A1C <7.0% at week 52 without confirmed/severe hypoglycemia with saxagliptin compared to GLIM when added to metformin (37.9% vs. 38.2%; OR: 0.99, 95% CI: 0.73, 1.34; P = 0.9415). However, it is noteworthy that saxagliptin was numerically (but not significantly) inferior for patients aged ≥75 years (35.9% vs. 45.5%).[119]

**Children and adolescents**

The evidence on the use of SUs in children is limited.[163] A 26-week, single-blind, active-controlled study, conducted in 285 pediatric patients with T2DM, found that GLIM was as effective as metformin in A1C reduction (~0.54%, P = 0.001 and −0.71%, P = 0.0002, respectively) with similar rates of hypoglycemia (4.9% vs. 4.2%, respectively).[164] Furthermore, a prospective trial evaluated the effect of SUs (mainly CHOL) in patients with Maturity-Onset Diabetes of the Young (MODY) patients with 9–29 years of age and found that long-term administration of SUs significantly enhanced glucose-induced insulin concentrations by approximately 68%.[165] Evidence and guidelines suggested that SUs are the drug of choice for the treatment of MODY.[166-168] Neonatal diabetes mellitus (NDM) is generally caused by several genetic abnormalities and might be either permanent or transient. In patients with NDM, SUs facilitate insulin secretion through the hormone GLP-1 pathway in response to food present in the gut. Evidence suggests that patients with permanent or transient NDM due to mutations in KCNJ11 or ABCC8 gene were successfully treated with SU (GLIB) therapy rather than insulin.[169,170] An observational case study reported that young children with neonatal diabetes even with blood glucose level of 350 mg/dL also responded to a usual dose of SU.[173]

**Pregnancy and lactation**

Second-generation SUs such as GLIB despite low molecular weight do not cross the placenta in significant amounts.[174] This phenomenon may be attributed either to its high protein-binding capacity (99.8%) or reverting the total GLIB content into the maternal system by an unidentified placental transport system. Furthermore, the absence of fetal adverse effects such as malformations and hypoglycemia makes GLIB an acceptable treatment option for patients with T2DM during pregnancy.[174,175] In a meta-analysis including one RCT from India, the outcomes of GLIB, metformin, and insulin were assessed. The study reported similar rate of cesarean delivery (range: 23%–52%) and infant birth weights (MD: −93 g, 95% CI: −191 to 5 g), with no significant difference in maternal glycemic control during the treatments.[176] Furthermore, a systemic review and meta-analysis reported no significant difference in terms of glycemic control or pregnancy outcomes between GLIB and insulin when used during pregnancy.[177] Moreover, in a meta-analysis, no significant difference was observed in the rate of neonatal major abnormality or neonatal death among women treated with GLIB-metformin compared with nonexposed women during first trimester; however, the study was limited by heterogeneity.[178] Nonetheless, long-term efficacy studies of GLIB during pregnancy and lactation are limited.[179] GLIB compared to metformin was more effective in lowering blood glucose in women with gestational diabetes with a lower treatment failure rate.[175] Moreover, there are some contradicting results from other studies and the paucity of data regarding the usage of SU combination therapy available during pregnancy and lactation.

**Patients with comorbidity**

Patients with diabetes are always at an increased risk of developing CVD. The risk of stroke, heart disease, and death due to heart disease is 2 folds high in patients with diabetes than in those without diabetes. Newer-generation SUs such as GLIM and GLIC MR reduce CV risk and may prevent protective ischemic cardiac preconditioning after MI.[179] In the ADVANCE trial, intensive glucose control with a GLIC-containing regimen has been shown to reduce the incidence of combined major macro- and microvascular events (18.1% vs. 20.0% with standard control; HR: 0.90; 95% CI: 0.82–0.98; P = 0.01), as well as that of major microvascular events (9.4% vs. 10.9%; HR: 0.86; 95% CI: 0.77–0.97; P = 0.01).[177] Similarly, the Veterans Affairs Diabetes Trial including 1791 military veterans (median follow-up: 5.6 years) reported that GLIM-based intensive regimen was associated with a 17% relative risk reduction in the rate of CV events compared to standard therapy.[13] Moreover, a recent meta-analysis demonstrates that SUs are not associated with increased risk for all-cause mortality, CV mortality, MI, or stroke.[38] SUs such as GLIP and GLIC are mainly excreted as unchanged drug or inactive metabolite. Therefore, they may produce less hypoglycemia in patients with renal impairment. GLIM has been reported to be safe and effective in diabetic patients with renal impairment.[180,181] However, GLIB may aggravate the risk of hypoglycemia in such populations.[182] Short-acting SUs such
### Table 12: Summary of randomized controlled trials comparing sulfonylureas versus other drugs as add on to metformin during Ramadan

| Author                | Interventions | Glycemic efficacy | Adverse events | Weight gain | Conclusion |
|-----------------------|---------------|-------------------|----------------|-------------|------------|
| Hassanein et al., 2014 | Vildaglutin (A) versus GLIC (B) | Adjusted mean change in A1C (A vs. B): 0.05%±0.04% versus −0.03%±0.04% (P=0.165) | Confirmed hypoglycemia (A vs. B): 3.0% versus 7.0% (P=0.039) | Adjusted mean difference in ↓ weight: −1.1±0.2 kg (P=0.987) for both groups | GLIC showed a lower incidence of hypoglycemia in the present study than previous studies |
| Brady et al., 2014    | Liraglutide (A) versus SUs (B) (GLIC, GLIM, GLIP or GLIB) | Change in A1C, 12 weeks post-Ramadan: A > B −0.3% versus +0.02% (P=0.05) | No episodes of severe hypoglycemia, however, self-recorded episodes of blood glucose ≤3.9 mmol/L: A < B (P=0.001) | Significant reductions in weight and diastolic BP in the A compared with B | Liraglutide compared with SU is well tolerated and maybe an effective therapy in combination with metformin |
| Azar et al., 2016     | Liraglutide versus SUs (GLIC, GLIM, GLIP, GLIB) | Similar ↓ fructosamine levels were observed for both groups; (liraglutide, −12.8 μmol/L; SU, −16.4 μmol/L; P=0.43) | No severe hypoglycemic episodes were reported by either group | ↓ Body weight more with liraglutide than SUs (ETD: −0.54 kg; P=0.0091) | Liraglutide showed similarly glycemic improvements, fewer hypoglycemic episodes than SU |
| Malha et al., 2014    | Vildaglutin versus (GLIC/GLIC) | Change in A1C from baseline to the last visit was similar for both groups | Hypoglycemic events was not statistically significant (P=0.334) between the groups | Weight control was improved after the fasting period for both groups | Vildaglutin may be a better agent than SU during Ramadan |
| Al Sifri et al., 2011 | Sitagliptin versus (GLIC/GLIC/GLIC/GLIC) | - Symptomatic hypoglycemia: Sitagliptin, 6.7%; GLIC, 6.6%; GLIM, 12.4%; GLIB, 19.7% | - | - | Incidence of hypoglycemia was lower with GLIC than other SUs and similar to sitagliptin |

ETD: Estimated treatment difference, SU: Sulfonylureas, T2DM: Type 2 diabetes mellitus, GLIC: Gliclazide, GLIM: Glimepiride, GLIP: Glipizide, GLIB: Glibenclamide, A1C: Glycated hemoglobin, BP: Blood pressure, ↓: decrease in

as GLIC and GLIP can be used with proper dose adjustment and monitoring in patients with renal insufficiency.[5] An RCT reported that in patients with chronic renal insufficiency, sitagliptin and GLIP provided similar A1C-lowering efficacy, and GLIP produced more hypoglycemia and weight gain than sitagliptin.[183] Furthermore, SUs should be cautiously used in patients with liver diseases, as most of the SUs are inactivated in the liver, they might accumulate in the body during liver dysfunction, and ultimately cause hypoglycemia. Moreover, in hypoalbuminemia, the concentration of free drug will increase and may produce hypoglycemia.[5,184] SUs with a short half-life such as GLIP or GLIB are preferred in liver disease patients. Patients with decompensated cirrhosis, i.e., encephalopathy, ascites, or coagulopathy, may have a reduced ability to counteract hypoglycemia, and thus, the response to therapy should be monitored closely.[185]

**Diabetes and Ramadan**

Patients who are continuing antidiabetic medications and undergoing fasting during Ramadan may encounter several difficulties such as hypoglycemia and other health-related complications.[5] Due to the increased risk of hypoglycemia, individuals with SUs should be careful during fasting period; however, some modern SUs (GLIC, GLIM, and GLIP) are associated with lower risk of hypoglycemia compared to GLIB.[90] The recent IDF-DAR practical guideline advocates that patients continuing second-generation SUs can fast safely during Ramadan.[186] The Glimepiride in Ramadan study reported that the efficacy and safety of GLIM have remained unchanged during the period of Ramadan in patients with T2DM.[187] In the STEADFAST study, there was no significant difference reported in hypoglycemic episodes between vildaglutin and GLIC (both add-ons to metformin) (P = 0.039).[188] Similarly, in Treat 4 Ramadan Trial, liraglutide compared to SUs (both add-ons to metformin) did not reveal any episodes of severe hypoglycemia in either group.[189] Table 12 summarizes the efficacy and safety of SU combination therapy during Ramadan. Incretin-based therapies such as DPP-4I and GLP-1 receptor agonist work by increasing insulin secretion in a glucose-dependent manner; therefore, they may not produce any risk of hypoglycemia. However, they may amplify the hypoglycemic effect of SUs when used in combination.[193] Studies conducted during Ramadan found higher hypoglycemic episodes with SUs compared to DPP-4I; however, subgroup analysis found GLIC having least hypoglycemic episodes among all SUs, almost similar to DPP-4I.[16,192]

**Diabetes and other fasting**

Fasting is a universal religio-cultural tradition observed in varying forms, in different religions across the world. Hindus observe fasting during Navaratri, Karva Chauth, and Guru Purnima; Buddhists observe during Lent; Jains observe in the occasion of Paryushana.[194-196] In the diabeto-centric viewpoint, patients taking antidiabetic agents should be monitored regularly for the event of hypoglycemia and other associated complications. Furthermore, the antidiabetic dose should be modified or omitted during the fasting period in order to prevent future complications. The dose modification or omission should be tailored according to the type of
Diabetes education and patient and physician empowerment

Due to chronic nature of the disease, diabetes necessitates self-management plan in day-to-day basis.\[200\] Diabetic education enables the patients to make informed decisions and effectively manage the disease without any complications. Diabetic education, which gives information on physical activity, glucose monitoring, diet, hypoglycemia, dosage and timing of medications, and identification of the symptoms of complications, should be provided to patients and their families. Patients should be encouraged and supported to become active partners in the decision-making process, to set realistic goals, select appropriate management strategies, enhance adherence, and improve treatment outcomes.\[5\] Self-monitoring of blood glucose (SMBG) at home and self-down titration of doses in case of hypoglycemia by patients are recommended. The patient should be trained for the safe use of FDC containing SUs and should be able to detect the hypoglycemic complications. Furthermore, patients along with their family members should be educated about the usage of SMBG system. When FDCs containing SUs are prescribed, physicians should consider the clinical profile of the patient and implement strategies that will not only help to minimize patient’s concerns over SUs treatment but also empower them for self-management. At each visit, physicians should look into symptoms suggestive of hypoglycemia and adjust doses accordingly when risks outweigh glycemic benefits.

Conclusion

Intensification of diabetic therapy with a proactive approach is crucial to achieve target glycemic levels. SUs are an important component of pharmacological armamentarium in the treatment of T2DM. Owing to their well-established efficacy and safety profile, they are the most commonly recommended class of agents when glycemic targets are not achieved with metformin alone. Owing to their disparity in pharmacokinetic and pharmacodynamic profile, which results in variability in safety and tolerability, the selection of SUs should be highly individualized with careful monitoring in high-risk patients. Due to their unique characteristics such as increased efficacy, CV safety, fewer episodes of hypoglycemia, and weight-neutralizing effects, modern SUs should be used over conventional SUs in the management of T2DM. Lower treatment cost without compromising the glycemic efficacy and tolerability together with good compliance rate positions SUs as the front-line agent in the management of T2DM. In addition, the complementary mechanisms of action of GLIM and metformin contribute to their enhanced glycemic effects. Appropriate patient selection, suitable drug and dose, along with proper patient and physician education may help in the effective and vigilant use of SUs in the management of T2DM.

Acknowledgment

The authors acknowledge Sanofi INDIA for supporting this initiative with an academic grant and Rabi Narayan Panigrahy,
Syam Kumar Yelamanchi, and Leena Patel from Jeevan Scientific Technology Limited (Hyderabad, India) for writing/editorial assistance in the development of this manuscript.

**Financial support and sponsorship**
This study was funded by Sanofi Diabetes India.

**Conflicts of interest**
There are no conflicts of interest.

**References**

1. International Diabetes Federation. The International Federation (IDF) Diabetes Atlas. 9th ed. Belgium: International Diabetes Federation; 2015. ISBN: 978-2-930229-81-2. Available from: [http://www.diabetesatlas.org/](http://www.diabetesatlas.org/). [Last accessed on 2017 Jan 25].

2. Global Report on Diabetes – World Health Organization; 2016. Available from: [http://wwwapps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf](http://wwwapps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf). [Last accessed on 2017 Jan 25].

3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-12.

4. Agarwal AA, Jadav PR, Deshmukh YA. Prescribing pattern and efficacy of anti-diabetic drugs in maintaining optimal glycaemic levels in diabetic patients. J Basic Clin Pharm 2014;5:79-83.

5. Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, Shrestha D, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in south Asia: A consensus statement. Indian J Endocrinol Metab 2015;19:577-96.

6. Truter I. An investigation into antidiabetic medication prescribing in South Africa. J Clin Pharm Ther 1998;23:417-22.

7. Chiang CW, Chiu HF, Chen CY, Wu HL, Yang CY. Trends in the use of oral antidiabetic drugs by outpatients in Taiwan: 1997-2003. J Clin Pharm Ther 2006;31:73-82.

8. Principal JK. A study on drug utilization of oral hypoglycemic agents in type-2 diabetic patients. Asian J Pharm Clin Res 2011;4:60-4.

9. Mandal S, Mariot T, Das AK, Das A, Mandal A, Sarkar BS, et al. Drug utilization study in patients with type 2 diabetes mellitus attending diabetes clinic of a tertiary care hospital in rural Bengal. Int J Basic Clin Pharm 2016;5:1647-54.

10. National List of Essential Medicines 2015, India. Available from: [http://wwwapps.who.int/medicinedocs/en/d/Js23088en/](http://wwwapps.who.int/medicinedocs/en/d/Js23088en/). [Last accessed on 2017 Mar 21].

11. Mkele G. What’s the latest on sulfonylures in the management of type 2 diabetes mellitus in South Africa? S Afr Fam Pract 2013;55:501-3.

12. Cahm A, Cefalu WT. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care 2016;39 Suppl 2:S137-45.

13. Hayward RA, Reaven PD, Wittala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;372:2197-206.

14. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: Systematic review and meta-analysis. Diabetes Obes Metab 2014;16:410-7.

15. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.

16. Derosa G, Sibilia S. Optimizing combination treatment in the management of type 2 diabetes. Vasc Health Risk Manag 2007;3:665-71.

17. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.

18. Del Prato S, Felton AM, Munro N, Nesto R, Zimmet P, Zinman B, et al. Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycemic goal. Int J Clin Pract 2005;59:1345-55.

19. Abrahamson MJ. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well! Diabetes Care 2015;38:166-9.

20. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of clinical endocrinologists and American College of endocrinology – Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan-2015. Endocr Pract 2015;21 Suppl 1:1-87.

21. Aquilante CL. Sulfonylurea pharmacogenomics in type 2 diabetes: The influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther 2010;8:359-72.

22. White JR Jr. A brief history of the development of diabetes medications. Diabetes Spectr 2014;27:82-6.

23. Quianzon CC, Cheikh IE. History of current non-insulin medications for diabetes mellitus. J Community Hosp Intern Med Perspect 2012;2:1-4.

24. Sarker A, Tiwari A, Bhasin PS, Mitra M. Pharmacological and pharmaceutical profile of gliclazide: A review. J Appl Pharm Sci 2011;1:11-9.

25. Oderda G, Richards K, Turpin S. Sulfonylurea Agents & Combination Products Drug Class Review. University of Utah College of Pharmacy, Final Report; July, 2013.

26. Lexi-Comp Inc., editor. Drug Information Handbook. 21 ed. Hudson, OH: Lexi-Comp Inc.; 2013.

27. Ballagi-Pordány G, Németh M, Aranyi Z, Kékesi E, Koltai MZ, Papp G, et al. Effect of gliclazide on the electrical activity of isolated rabbit heart muscle. Arzneimittelforschung 1992;42:111-3.

28. Nakamura I, Oyama J, Komoda H, Shiraki A, Sakamoto Y, Taguchi I, et al. Possible effects of gliclazide beyond glycemic control in patients with type 2 diabetes: A preliminary report. Cardiovasc Diabetol 2014;13:15.

29. Ashcroft FM, Gribble FM. Tissue-specific effects of sulfonylureas: Lessons from studies of cloned K(ATP) channels. J Diabetes Complications 2000;14:192-6.

30. Gribble FM, Ashcroft FM. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 2000;49:3-6.

31. Vila-Carriles WH, Zhao G, Bryan J. Defining a binding pocket for sulfonylureas in ATP-sensitive potassium channels. FASEB J 2007;21:18-25.

32. Thulé PM, Umpierrez G. Sulfonylureas: A new look at old therapy. Curr Diab Rep 2014;14:473.

33. Kramer W, Müller G, Girbig F, Gutjahr U, Kowalewski S, Hartz D, et al. Differential interaction of gliclazide and glibenclamide with the beta-cell sulfonylurea receptor II. Photoaffinity labeling of a 65 kDa protein by [3H] gliclazide. Biochem Biophys Acta 1994;1191:278-90.

34. Briscoe VJ, Griffith ML, Davis SN. The role of glimepiride in the management of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2010;6:225-35.

35. Holstein A, Plauschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with gliclazide versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-73.

36. Singh AK, Singh R. Is gliclazide a sulfonylurea with difference? A review. Indian J Basic Clin Pharm 2014;5:15.

37. Oderda GM, Richards K, Turpin S. Sulfonylurea Agents & Combination Products Drug Class Review. University of Utah College of Pharmacy, Final Report; July, 2013.

38. Gribble FM, Ashcroft FM. Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 2000;49:3-6.

39. Quianzon CC, Cheikh IE. History of current non-insulin medications for diabetes mellitus. J Community Hosp Intern Med Perspect 2012;2:1-4.

40. Sarker A, Tiwari A, Bhasin PS, Mitra M. Pharmacological and pharmaceutical profile of gliclazide: A review. J Appl Pharm Sci 2011;1:11-9.

41. Oderda G, Richards K, Turpin S. Sulfonylurea Agents & Combination Products Drug Class Review. University of Utah College of Pharmacy, Final Report; July, 2013.
clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm-2017 executive summary. Endocr Pract 2017;23:207-38.

42. American Diabetes Association. Standards of Medical Care in Diabetes; 2017. Available from: http://www.professional.diabetes.org/sites/professional.diabetes.org/files/media/de_40_s1_final.pdf. [Last accessed on 2017 Feb 24].

43. Ministry of Health, Kingdom of Bahrain. Guidelines for Management of Type 2 Diabetes Mellitus in Primary Care Settings and Outpatient Clinics in the Kingdom of Bahrain. Available from: http://www.mhra.bh/files/CEO/Hypertension%20Guideline%2030152015.pdf. [Last accessed on 2017 Mar 08].

44. Chinye PE, Ogbeh EN, Onyemelukwe GC, Uloko AE, Ogboya AO. Clinical Practice Guidelines for Diabetes Management in Nigeria. Diabetes Association of Nigeria (DAN); 2013.

45. Rutten GE, De Grauw WJ, Nijpels G, Hovingh GT, van der Heijden HGM, van der Meer M, et al. Effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta-analysis. Diabetologia 2013;56:973-84.

46. Diabetes Mellitus Guidelines, WHO EMRO; 2006. Available from: http://wwwapplications.emro.who.int/dsaf/dsa646.pdf. [Last accessed on 2017 Apr 06].

47. National Clinical Guidelines for Management of Diabetes Mellitus; Republic of Kenya Ministry; 2010.

48. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract 2014;104:1-52.

49. Type 2 Diabetes in Adults: Management, NICE Guideline [NG28]; 2015. Available from: https://www.nice.org.uk/guidance/ng28/2016/01/16316820. [Last accessed on 2017 Mar 14]

50. Madhu SV, Saboo B, Makkar BM, Reddy GC, Jana J, Panda JK, et al. RSSDI clinical practice recommendations for management of type 2 diabetes mellitus, 2015. Int J Diabetes Dev Ctries 2015;35:1-71.

51. Mishra S, Ray S, Dalal JJ, Sawhney JP, Ramakrishnan S, Nair T, et al. Management protocols of stable coronary artery disease in India: Executive summary. Indian Heart J 2016;68:686-73.

52. The Society for Endocrinology, Metabolism and Diabetes of South Africa Type 2 Diabetes Guidelines Expert Committee. The 2017 SEMDSA Guideline for the Management of Type 2 Diabetes Guidelines Expert Committee. JEMDSA 2017;21(Supplement 1): S1-S196.

53. The United Republic of Tanzania, Standard Treatment Guidelines and Essential Medicines List; Ministry of Health and Social Welfare. 4th ed.; May, 2013.

54. National Diabetes Guidelines, United Arab Emirates; 2009. Available from: cms.wounds-uk.com/media/NationalDiabetesGuidelinesUAE.pdf [Last accessed on 2017 Mar 08].

55. The Republic of Uganda, Ministry of Health, National Guidelines for Management of Common Conditions; Uganda Clinical Guidelines; 2016.

56. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-9.

57. Del Prato S, Vigili de Kreutzenberg S, Riccio A, Tiengo A. Hepatic sensitivity to insulin: Effects of sulfonylurea drugs. Am J Med 1991;90:295-365.

58. Ramacheya R, Ward C, Shigeto M, Walker JN, Amisten S, Zhang Q, et al. Membrane potential-dependent inactivation of voltage-gated ion channels in alpha-cells inhibits glucagon secretion from human islets. Diabetes 2010;59:2198-208.

59. Bolen S, Tseng E, Hutfless S, Segal JB, Suarez-Cuervo C, Berger Z, et al. Diabetes Medications for Adults with Type 2 Diabetes: An Update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016. Available from: http://www.ncbi.nlm.nih.gov/books/NBK362863/. [Last accessed on 2017 Jan 12]

60. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating the effect of sulfonylurea on HbA1c in diabetes: A systematic review and meta-analysis. Diabetologia 2013;56:973-84.

61. Ahrén B, Johnson SL, Stewart M, Cirkel DT, Yang F, Perry C, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care 2014;37:2141-8.

62. Kim HS, Kim DM, Cha BS, Park TS, Kim KA, Kim DL, et al. Efficacy of glimepiride/metformin fixed-dose combination vs. metformin up titration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea. J Diabetes Investig 2014;5:701-8.

63. Kalra S, Das AK. Epidemiologic surveillance of glycemic response to a scored, breakable, extended release, fixed dose combination of glimepiride and metformin in persons with type 2 diabetes. J Assoc Physicians India 2017;65:38-41.

64. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001;18:828-34.

65. González-Ortiz M, Martínez-Abundis E; Grupo para el Tratamiento de la Diabetes Mellitus con Combinaciones. Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glinidamide, as monotherapy. Rev Invest Clin 2004;56:327-33.

66. Ritchie S, Collober-Maugeais C, Cressier F, Tang P, Pecher E. Nateglinide or glimepiride in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. Diabetes Obes Metab 2007;9:506-11.

67. Goldstein BJ, Pans M, Rubin CJ. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/ metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea. Clin Ther 2003;25:890-903.

68. Feinglos M, Dailey G, Cefalu W, Osei K, Tayek J, Canovatchel W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 2005;68:167-75.

69. Marre M, Howlett H, Lebert P, Allavoine T. Improved glycaemic control with metformin-glinidamide combined tablet therapy (Glucovan) in type 2 diabetic patients inadequately controlled on metformin. Diabet Med 2002;19:673-80.

70. Chien HH, Chang CT, Chu NF, Hsieh SH, Huang YY, Lee IT, et al. Effect of glyburide/metformin combination tablet in patients with type 2 diabetes. J Chin Med Assoc 2007;70:473-80.

71. Ray JA, Huet D, Valentine WJ, Palmer AJ, Cugnardey N, Renaudin C, et al. Long-term costs and clinical outcomes associated with metformin-glinidamide combination tablets (Glucovan®) in patients with type 2 diabetes sub-optimally controlled by metformin: A modelling study in the French setting. Br J Diabetes Vasc Dis 2008;8:39-44.

72. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: Results of a randomized clinical trial. Curr Med Res Opin 2006;22:751-9.

73. Lee YK, Song SO, Kim KJ, Cho Y, Choi Y, Yun Y, et al. Glycemic effectiveness of metformin-based dual-combination therapies with sulphonylurea, pioglitazone, or DPP4-inhibitor in drug-naive Korean type 2 diabetic patients. Diabetes Metab J 2013;37:465-74.

74. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Scherhagener M. Long-term therapy with addition of pioglitazone to metformin compared with the addition of glimepiride to metformin in patients with type 2 diabetes: A randomized, comparative study. Diabetes Metab Res Rev 2005;21:167-74.

75. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2015;109:378-88.

76. Zhou JB, Bai L, Wang Y, Yang JK. The benefits and risks of DPP4-inhibitors vs. sulfonylureas for patients with type 2 diabetes: Accumulated evidence from randomised controlled trial. Int J Clin Pract 2016;70:132-41.

77. Amate JM, Lopez-Cuadrado T, Almendro N, Bouza C, Saz-Parkinson Z, Rivas-Ruiz R, et al. Effectiveness and safety of glimepiride and IDPP4,
associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: Systematic review and meta-analysis. Int J Clin Pract 2015;69:292-304.

78. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with type 2 diabetes inadequately controlled with metformin alone: A 52-week, randomized study. Diabet Med 2010;27:318-26.

79. Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial. Int J Clin Pract 2010;64:1619-31.

80. Thomsen RW, Baggesen LM, Sogaard M, Pedersen L, Nørrelund H, Buhl ES, et al. Early glycaemic control in metformin users receiving their first add-on therapy: A population-based study of 4,734 people with type 2 diabetes. Diabetologia 2015;58:2247-53.

81. Riddërstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedel UC, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: A 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2015;3:691-700.

82. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50.

83. Nauck MA, Durán-García S, Maffei L, Rohwedder K, Thamerkauf A, et al. Long-term glycemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 2015;17:581-90.

84. Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, Basson BR, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): An open-label, randomised controlled trial. Lancet 2012;379:2270-8.

85. Mamza J, Mehta R, Donnelly R, Idris I. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: A retrospective cohort study. Ann Med 2016;48:224-34.

86. Palmertz A, Schöndorf T, Tschöpe D, Lobmann R, Merke J, et al. PIOlfX-study: Effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther 2011;13:637-43.

87. Prentice JC, Conlin PR, Sellad WF, Edelman D, Lee TA, Pizer SD, et al. Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. Value Health 2014;17:854-62.

88. Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-β1 and type 4 collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res 2012;35:483-8.

89. Comaschi M, Demicheli A, Di Pietro C, Bellatreccia A, Mariz S; COM06 Study Investigators. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. Diabetes Technol Ther 2007;9:387-98.

90. Palmertz A, Schöndorf T, Tschöpe D, Lohmann R, Merke J, Müller J, et al. PIOlfX-study: Effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther 2011;13:637-43.

91. Prentice JC, Conlin PR, Sellad WF, Edelman D, Lee TA, Pizer SD, et al. Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. Value Health 2014;17:854-62.

92. Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-β1 and type 4 collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res 2012;35:483-8.

93. Comaschi M, Demicheli A, Di Pietro C, Bellatreccia A, Mariz S; COM06 Study Investigators. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. Diabetes Technol Ther 2007;9:387-98.

94. Palmertz A, Schöndorf T, Tschöpe D, Lohmann R, Merke J, Müller J, et al. PIOlfX-study: Effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther 2011;13:637-43.

95. Prentice JC, Conlin PR, Sellad WF, Edelman D, Lee TA, Pizer SD, et al. Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. Value Health 2014;17:854-62.

96. Zhang H, Zhang X, Hu C, Lu W. Exenatide reduces urinary transforming growth factor-β1 and type 4 collagen excretion in patients with type 2 diabetes and microalbuminuria. Kidney Blood Press Res 2012;35:483-8.

97. Comaschi M, Demicheli A, Di Pietro C, Bellatreccia A, Mariz S; COM06 Study Investigators. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. Diabetes Technol Ther 2007;9:387-98.

98. Palmertz A, Schöndorf T, Tschöpe D, Lohmann R, Merke J, Müller J, et al. PIOlfX-study: Effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther 2011;13:637-43.

99. Prentice JC, Conlin PR, Sellad WF, Edelman D, Lee TA, Pizer SD, et al. Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. Value Health 2014;17:854-62.
Niskanen L, Östgren CJ, et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: A randomized, controlled study (GENERATION). Diabetes Obes Metab 2015;17:630-8.

111. Ishii H, Okubo Y, Takei M, Nishio S, Yamazaki M, Kumagai M, et al. Efficacy of combination therapy with sitagliptin and low-dose glimepiride in Japanese patients with type 2 diabetes. J Clin Med Res 2014;6:127-32.

112. Komatsu M, Takei M, Ishii H, Sato Y. Glucose-stimulated insulin secretion: A newer perspective. J Diabetes Investig 2013;4:511-6.

113. Yabe D, Seiino Y. Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe? J Diabetes Investig 2014;5:475-7.

114. McCluskey D, Touger MS, Melis R, Schleusener DS, McCluskey D. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy. Clin Ther 2004;26:1783-90.

115. Chou HS, Palmer JP, Jones AR, Waterhouse B, Ferreira-Cornwell C, Krebs J, et al. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. Diabetes Obes Metab 2008;10:626-37.

116. Hanefeld M, Brunetti P, Schenhammer GH, Matthews DR, Charbonnel BH; QUARTET Study Group. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:1417.

117. Shimoda S, Iwashita S, Sekigami T, Furukawa N, Matsuo Y, Ichimori S, et al. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination. J Diabetes Investig 2014;5:320-6.

118. Harashima SI, Ogura M, Tanaka D, Fukushima T, Wang Y, Koizumi T, et al. Sitagliptin add-on to low-dose sulphonylureas: Efficacy and safety of combination therapy on glycemic control and insulin secretion capacity in type 2 diabetes. Int J Clin Pract 2012;66:465-76.

119. Roberts VL, Stewart J, Isha M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: Results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2005;27:1535-47.

120. Arai K, Maeda H, Sirabe S, Yamamoto R, Yamauchi M, Hirao T, et al. Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus. Diabetes Technol Ther 2013;15:335-41.

121. Downes MJ, Bettington EK, Gunton JE, Turkstra E. Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. PeerJ 2015;3:e1461.

122. Derosa G, Cicero AF, D’Angelo A, Gaddi A, Piccirella L, Piccimi MN, et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: A multicenter, randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2006;28:679-88.

123. Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Clin Ther 2007;29:1900-14.

124. Umayahara R, Yonemoto T, Kyosa C, Morishita K, Ogawa T, Taguchi Y, et al. Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride. Endocr J 2014;61:1163-70.

125. Schenhammer G, Rosas-Guzmán J, Dotta F, Guerci B, Simó R, Festa A, et al. Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: Results from the prospective European Exenatide (EUREXA) study. Diabetes Obes Metab 2015;17:689-98.

126. Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, parallel-group trial. Clin Ther 2004;26:744-54.

127. Meshram DM, Langade DG, Kinagi SB, Naikwadi AA, Morve V, Chopra D, et al. Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg plus pioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus. J Indian Med Assoc 2005;103:447-50.

128. Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci 2015;11:840-8.

129. Lebovitz HE, Pasmanter R. Combination insulin-sulfonylurea therapy. Diabetes Care 1990;13:667-75.

130. Groop LC, Groop PH, Stenman S. Combined insulin-sulfonylurea therapy in treatment of NIDDM. Diabetes Care 1990;13 Suppl 3:47-52.

131. Zhou J, Zheng F, Guo X, Yang H, Zhang M, Tian H, et al. Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs. Diabetes Metab Res Rev 2015;31:725-33.

132. Schiel R, Müller UA. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: The SWITCH pilot study. Exp Clin Endocrinol Diabetes 2008;116:58-64.

133. Janka HU, Pielew G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007;55:182-8.

134. Standl E, Maxeiner S, Raptis S, Karimi-Anderesi Z, Schweitzer MA; HOE901/4009 Study Group. Good glycemic control with flexibility in timing of basal insulin supply: A 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 2005;28:419-20.

135. Olsson PO, Lindström T. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. Diabetes Metab 2002;28:272-7.

136. Park CY, Kang JG, Chon S, Noh J, Oh SJ, Lee CB, et al. Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes. PLoS One 2014;9:e87799.

137. Li CJ, Zhang JY, Yu DM, Zhang QM. Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes. Diabetol Metab Syndr 2014;6:41.

138. Vos RC, van Avendonk MJ, Jansen H, Goudwaard AN, van den Donk M, Gotter K, et al. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. Cochrane Database Syst Rev 2016;9:CD006992.

139. Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ, et al. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care 1992;15:953-9.

140. Esposito K, Ciottola M, Maiorino MI, Gualdiiero S, Schisano B, Ceriello A, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycaemic control: A randomized trial. Ann Intern Med 2008;149:531-9.

141. Janka HU, Pielew G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9.

142. Wright A, Burden AC, Paisley RB, Cull CA, Holman RR; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes already on treatment. Ann Intern Med 2004;141:589-96.

143. Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkiö M, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999;130:389-96.
Kalra, et al.: Sulfonylurea and combinations: International Task Force

144. Holman RR, Thorne KL, Farmer AJ, Davies MJ, Keenan JF, Paul S, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30.

145. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736-47.

146. Stuart CA, Gilkison CR, Carlson RF, Stuart CA, Gilkison CR, Carlson RF, et al. Effect of adding a sulfonylurea in patients with non-insulin-dependent diabetes mellitus previously well controlled with insulin. Endo Pract 1997;3:344-8.

147. Riddle M, Hart J, Bingham P, Garrison C, McDaniel P. Combined therapy for obese type 2 diabetes: Support mixed insulin with daytime sulfonylurea. Am J Med Sci 1992;303:151-6.

148. Chale SS, Swai AB, Mujinja PG, McLarty DG. Must diabetes be a fatal disease in Africa? Study of costs of treatment. BMJ 1992;304:1215-8.

149. Zhang Y, McCoy RG, Mason JE, Smith SA, Shah ND, Benton DT, et al. Second-line agents for glycermic control for type 2 diabetes: Are newer agents better? Diabetes Care 2014;37:1338-45.

150. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med 2008;23:614-1.

151. Saini SD, Schoenfeld P, Kauflack Back, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15:e22-33.

152. Meece J. Improving medication adherence among patients with type 2 diabetes. J Pharm Pract 2014;27:187-94.

153. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007;120:713-9.

154. Blonde L, San Juan ZT. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther 2012;29:1-3.

155. Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000;108 Suppl 6a:15S-22S.

156. Kalra S. Aggressive treatment in newly diagnosed diabetes with fixed dose combinations. Medicine 2012;22:249-53.

157. Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: A meta-analysis. Curr Med Res Opin 2011;27:309-18.

158. Huchinson V, Zhang B, Florence RL, Krishnarajah G, Graham J. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin 2011;27:1157-68.

159. Drouin P, Stand E, Diamioncr MR Study Group. Gliclazide modified release: Results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab 2004;6:414-21.

160. Chanal H. Should elderly patients with type 2 diabetes be treated with glibenclamide (glyburide) or different sulphonylurea? Geneva: World Health Organization; 2013.

161. International Diabetes Federation, Managing Older People with Type 2 Diabetes. Global Guideline 2013. Available from: https://www.idf.org/e-library/guidelines/78-global-guideline-for-managing-older-people-with-type-2-diabetes.html [Last accessed on 2017 Apr 27].

162. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Meneilly GS, Knip A, Tessler D. Diabetes in the elderly. J Can Diabetes Stud 2006;23:611-4.

163. Onge ES, Miller SA, Motycza C, DeBerry A. A review of the treatment of type 2 diabetes in children. J Pediatr Pharmacol Ther 2015;20:4-16.

164. Gottschalk D, Manor T, Vlajnic A, Cara JF. Glibenclamide versus metformin as monotherapy in pediatric patients with type 2 diabetes: A randomized, single-blind comparative study. Diabetes Care 2007;30:790-4.

165. Fajans SS, Brown MB. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young. Diabetes Care 1993;16:1254-61.

166. Rasen K, Schober E, Konrad K, Tshon A, Grulich-Henn J, Meissner T, et al. Treatment of young patients with HNF1A mutations (HNF1A-MODY). Diabet Med 2015;32:526-30.

167. Thanabalasingham G, Owen KR. Diagnosis and management of maturity onset diabetes of the young (MODY). BMJ 2011;343:d6044.

168. Hansa R, Donahue K, Klingensmith G, Swift P, Colagiuri S. Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence. Brussels: International Diabetes Federation; 2011.

169. Oztokin O, Durmaz E, Kalay S, Flanagan SE, Ellard S, Bircan I, et al. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a novel missense mutation, p.P1199L, in the ABC8 gene. J Perinatol 2012;32:645-7.

170. Pearson ER, Fleethner J, Njalstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:367-77.

171. Babenko AP, Polak M, Czav H, Bushay K, Czernichow P, Scharfmann R, et al. Activating mutations in the ABC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355:456-66.

172. Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baever H, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding kir6.2: Patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004;53:2713-8.

173. Cnoder E, Flanagan SE, Ugarte F, Garcia H, Vidal T, Ellard S, et al. Sulfonylurea treatment in young children with neonatal diabetes: Dealing with hyperglycemia, hypoglycemia, and sick days. Diabetes Care 2007;30:e28-9.

174. Kavitha N, De S, Kanagasabai S. Oral hypoglycemic agents in pregnancy: An update. J Obstet Gynaecol India 2013;63:82-7.

175. Kalra B, Gupta Y, Single A, Kalra S. Use of oral anti-diabetic agents in pregnancy: A pragmatic approach. N Am J Med Sci 2015;7:6-12.

176. Nicholson W, Bolen S, Witkop CT, Neale D, Wilson L, Bass E, et al. Benefits and risks of oral diabetes agents compared with insulin in women with gestational diabetes: A systematic review. Obstet Gynecol 2009;113:193-205.

177. Dhulkotia JS, Ola B, Fraser R, Farrell T. Oral hypoglycemic agents vs. insulin in management of gestational diabetes: A systematic review and metaanalysis. Am J Obstet Gynecol 2010;203:457.e1-9.

178. Gutzin SI, Koezer E, Magee LA, Feig DS, Kongen G. The safety of oral hypoglycemic agents in the first trimester of pregnancy: A meta-analysis. Can J Clin Pharmacol. 2003;10:179-83.

179. Azimova K, San Juan Z, Mukherjee D. Cardiovascular safety profile of currently available diabetic drugs. Ochsner J 2014;14:616-32.

180. Ioannis D. Diabetes treatment in patients with renal disease: Is the landscape clear enough? World J Diabetes 2014;5:651-8.

181. Rosenkranz B, Profzie V, Metelko Z, Mrzljak V, Lange C, Malerczyk V, et al. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996;39:1617-24.

182. van Dalem J, Brouwers MC, Stenhauer CD, Krings A, Leukhens HG, Driessen JH, et al. Risk of hypoglycemia in users of sulphonylurea compared with metformin in relation to renal function and sulphonylurea metabolite group: Population based cohort study. BMJ 2016;354:i3625.

183. Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Holm GT, Sisk CM, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013;36:1067-73.

184. Saini JS. Management guidelines for use of oral hypoglycemic agents (OHA) in complex clinical situations and important drug interactions with OHA's. Acta Endocrinol 1991;108:85-90.

185. Tolman KG, Fonseca V, Dalpaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007;30:734-43.

186. Hassanein O, Al-Arouj M, Hamdy O, Bebaker WM, Jabbar A, Al-Madani A, et al. Diabetes and Ramadan: Practical guidelines. Diabetes Res Clin Pract 2017;126:303-16.

187. Glimpiride in Ramadan (GLIRA) Study Group. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005;28:421-2.

188. Hassanein M, Abbaldah K, Schweizer A. A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: The
189. Brady EM, Davies MJ, Gray LJ, Saeed MA, Smith D, Hanif W, et al. A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: The treat 4 Ramadan trial. Diabetes Obes Metab 2014;16:527-36.

190. Azar ST, Echtay A, Wan Bebakar WM, Al Araj S, Berra A, Omar M, et al. Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): A randomized trial. Diabetes Obes Metab 2016;18:1025-33.

191. Malha LP, Taan G, Zantout MS, Azar ST. Glycemic effects of vildagliptin in patients with type 2 diabetes before, during and after the period of fasting in Ramadan. Ther Adv Endocrinol Metab 2014;5:3-9.

192. Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, et al. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: A randomised trial. Int J Clin Pract 2011;65:1132-40.

193. Almalki MH, Alshahrani F. Options for controlling type 2 diabetes during Ramadan. Front Endocrinol (Lausanne) 2016;7:32.

194. Kalra S, Bajaj S, Gupta Y, Agarwal P, Singh SK, Julka S, et al. Fasts, feasts and festivals in diabetes-1: Glycemic management during Hindu fasts. Indian J Endocrinol Metab 2015;19:198-203.

195. Latt TS, Kalra S. Managing diabetes during fasting – A focus on Buddhist lent. Diabetes Voice 2012;57:42-5.

196. Julka S, Sachan A, Bajaj S, Sahay R, Chawla R, Agrawal N, et al. Glycemic management during Jain fasts. Indian J Endocrinol Metab 2017;21:238-41.

197. Glylade: Gliclazide Tablets: Label Information of TGA. Available from: http://www.medicines.org.au/files/afpglyad.pdf. [Last accessed on 2015 Mar 25].

198. Glyburide Tablets. Label Information of FDA. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017532Orig1s034lbl.pdf. [Last accessed on 2015 Mar 25].

199. Amaryl: Glimepiride Tablets. Label Information of FDA. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020496s027lbl.pdf. [Last accessed on 2015 Mar 25].

200. Powers MA, Bardsley J, Cypress M, Duker P, Funnell MM, Fischl AH, et al. Diabetes self-management education and support in type 2 diabetes: A joint position statement of the American Diabetes Association, the American association of diabetes educators, and the academy of nutrition and dietetics. Diabetes Educ 2015;41:417-30.